Chronic fatigue syndrome (CFS) is one of several names given to a poorly understood, variably debilitating disorder of uncertain cause/causes. ME/CFS nomenclatures are varied and ME/CFS does not have a potentially definitive name that is free of controversy.
Based on a 1999 study of adults in the United States, CFS is thought to affect approximately 4 per 1,000 adults. For unknown reasons, CFS occurs more often in women, and adults in their 40s and 50s. The illness is estimated to be less prevalent in children and adolescents, but study results vary as to the degree.
CFS often manifests with cognitive difficulties, chronic mental and physical exhaustion, often severe, and other characteristic symptoms in a previously healthy and active person. Despite promising avenues of research, there remains no assay or pathological finding which is widely accepted to be diagnostic of CFS. It remains a diagnosis of exclusion based largely on patient history and symptomatic criteria, although a number of tests can aid diagnosis. Whereas there is agreement on the genuine threat to health, happiness, and productivity posed by CFS, various physicians' groups, researchers, and patient activists champion very different nomenclature, diagnostic criteria, etiologic hypotheses, and treatments, resulting in controversy about nearly all aspects of the disorder. Even the term chronic fatigue syndrome is controversial because a large part of the patient community believes the name trivializes the illness.
Chronic fatigue syndrome is not the same as "chronic fatigue”. Fatigue is a common symptom in many illnesses, but CFS is a multi-systemic disease and is relatively rare by comparison. Definitions (other than the 1991 UK Oxford criteria) require a number of features, the most common being severe mental and physical exhaustion which is "unrelieved by rest" (1994 Fukuda definition), and may be worsened by even trivial exertion (a mandatory diagnostic criterion according to some systems). Most diagnostic criteria require that symptoms must be present for at least six months, and all state the symptoms must not be caused by other medical conditions. CFS patients may report many symptoms which are not included in all diagnostic criteria, including muscle weakness, cognitive dysfunction, hypersensitivity, orthostatic intolerance, digestive disturbances, depression, poor immune response, and cardiac and respiratory problems. It is unclear if these symptoms represent co-morbid conditions or are produced by an underlying etiology of CFS. Some cases improve over time, and treatments (though none are universally accepted) bring a degree of improvement to many others, though full resolution may be rare, only 5-10% according to the United States Centers for Disease Control and Prevention (CDC).
The naming of chronic fatigue syndrome has been challenging, since consensus is lacking within the medical, research, and patient communities regarding the defining features of the syndrome. It may be considered by different authorities to be a central nervous system, metabolic, (post-)infectious, immune system or neuropsychiatric disorder.
There are a number of different terms which have been identified at various times with this disorder.
- Myalgic encephalomyelitis or ME translates to "inflammation of the brain and spinal cord with muscle pain" and first appeared as "benign myalgic encephalomyelitis" in a Lancet editorial by Sir Donald Acheson in 1956. In a 1959 review he referred to several older reports that appeared to describe a similar syndrome. The neurologist Lord Brain included ME in the 1962 sixth edition of his textbook of neurology, A 1978 British Medical Journal article stated the Royal Society of Medicine conference to discuss the illness during that year clearly agreed Myalgic Encephalomyelitis was a distinct name for the disease. The article also stated the previous word (benign) used with ME was rejected as unsatisfactory and misleading because the condition may be devastating to the patient. In 1988 both the UK Department of Health and Social Services and the British Medical Association officially recognized it as a legitimate and potentially distressing disorder.[How to reference and link to summary or text] Opponents of the term ME state that there is no objective evidence of inflammation. In some patients diagnosed with CFS (e.g. the case of Sophia Mirza), central nervous system inflammation has been documented. Many patients, and some research and medical professionals in the United Kingdom and Canada, use this term in preference to or in conjunction with CFS (ME/CFS or CFS/ME). The international association of researchers and clinicians is named IACFS/ME.
- Myalgic encephalopathy, similar to the above, with "pathy" referring to unspecified pathology rather than inflammation; this term has some support in the UK and US.
- Chronic Epstein-Barr virus (CEBV) or Chronic Mononucleosis; the term CEBV was introduced in 1985 by virologists Dr. Stephen Straus and Dr. Jim Jones in the United States. The Epstein-Barr virus, a neurotropic virus that more commonly causes infectious mononucleosis, was thought by Straus and Jones to be the cause of CFS. Subsequent discovery of the closely related human herpesvirus 6 shifted the direction of biomedical studies, although a vastly expanded and substantial body of published research continues to show active viral infection or reinfection of CFS patients by these two viruses. These viruses are also found in healthy controls, lying dormant.
- Chronic fatigue syndrome (CFS) was proposed in 1988 by researchers from the U.S. Centers for Disease Control and Prevention (CDC) to replace the name chronic Epstein-Barr virus syndrome when they published an initial case definition for research of the illness after investigating the 1984 Lake Tahoe ME epidemic. CFS is used increasingly over other designations, particularly in the United States. Many patients and clinicians perceive the term as trivializing, and as the 1994 Fukuda paper itself cedes, stigmatizing, which led to a movement in the United States to change the name and definition. Eighty-five percent of respondents to a 1997 survey conducted by the Chronic Fatigue Immune Dysfunction Syndrome Association of America wanted the name changed. The CFS Coordinating Committee (CFSCC) of the U.S. Department of Health and Human Services formed a name change workgroup in 2000. Terms were recommended which implied specific underlying etiologies or pathologic processes, but work was shelved in December 2003 when the successor CFS Advisory Committee (CFSAC) decided a name change would be too disruptive at that time.
- Chronic fatigue immune dysfunction syndrome (CFIDS); many patients and advocacy groups in the USA use the term CFIDS, in an attempt to reduce the psychiatric stigma attached to "chronic fatigue," as well as the public perception of CFS as a psychiatric syndrome. The term also calls attention to the immune dysfunction in patients which research suggests is an integral part of the illness.
- Post-viral fatigue syndrome (PVFS); this is a related disorder. According to ME researcher, Dr. Melvin Ramsay, "The crucial differentiation between ME and other forms of post-viral fatigue syndrome lies in the striking variability of the symptoms not only in the course of a day but often within the hour.
- Low Natural Killer Syndrome (LNKS); this term reflected research on patients showing diminished in-vitro natural killer cell activity in a small 1987 study in Japan. A case definition for CFS in Japan was adopted in 1991 based on the CDC 1988 criteria, an updated diagnostic guideline is planned.
- Yuppie Flu; this was a factually inaccurate term first published in a November 1990 Newsweek cover story and never official medical terminology. It reflects a stereotypical assumption that CFS mainly affects the affluent ("yuppies"), and implies that it is a form of burnout. CFS, however, affects people of all races, genders, and social standings, and is not a form of flu. The phrase is considered offensive by patients and clinicians.
- Uncommonly used terms include Akureyri Disease, Iceland disease (in Iceland), Royal Free disease (after the location of an outbreak), atypical poliomyelitis, epidemic neuromyasthenia, epidemic vasculitis, raphe nucleus encephalopathy, and Tapanui flu (after the New Zealand town Tapanui where the first doctor in the country to investigate the disease, Dr Peter Snow, lived).
Signs and symptomsEdit
Sudden onset casesEdit
The majority of CFS cases start suddenly, usually accompanied by a "flu-like illness" which is more likely to occur in winter, while a significant proportion of cases begin within several months of severe adverse stress. Many people report getting a case of a flu-like or other respiratory infection such as bronchitis, from which they seem never to fully recover and which evolves into CFS. The diagnosis of Post Viral Fatigue Syndrome is sometimes given in the early stage of the illness. One study reported CFS occurred in some patients following a vaccination or a blood transfusion. The accurate prevalence and exact roles of infection and stress in the development of CFS however are currently unknown.
Gradual onset casesEdit
Other cases have a gradual onset, sometimes spread over years. Patients with Lyme disease may, despite a standard course of treatment, "evolve" clinically from the symptoms of acute Lyme to those similar to CFS. This has become an area of great controversy.
It can be inferred from the 2003 "Canadian" clinical working definition of ME/CFS that there are 8 categories of symptoms:
- Fatigue: Unexplained, persistent, or recurrent physical and mental fatigue/exhaustion that substantially reduces activity levels and is not relieved (or not completely relieved) by rest.
- Post-exertional malaise: An inappropriate loss of physical and mental stamina, rapid muscular and cognitive fatigability, post exertional malaise and/or fatigue and/or pain and a tendency for other associated symptoms to worsen with a pathologically slow recovery period of usually 24 hours or longer. According to the authors of the Canadian clinical working definition of ME/CFS, the malaise that follows exertion is often reported to be similar to the generalized pain, discomfort and fatigue associated with the acute phase of influenza. Although common in CFS, this may not be the most severe symptom in the individual case, where other symptoms (such as headaches, neurocognitive difficulties, pain and sleep disturbances) can dominate.
- Sleep dysfunction: "Unrefreshing" sleep/rest, poor sleep quantity, insomnia or rhythm disturbances. A study found that most CFS patients have clinically significant sleep abnormalities that are potentially treatable. Several studies suggest that while CFS patients may experience altered sleep architecture (such as reduced sleep efficiency, a reduction of deep sleep, prolonged sleep initiation, and alpha-wave intrusion during deep sleep) and mildly disordered breathing, overall sleep dysfunction does not seem to be a critical or causative factor in CFS. Sleep may present with vivid disturbing dreams, and exhaustion can worsen sleep dysfunction.
- Pain: Pain is often widespread and migratory in nature, including a significant degree of muscle pain and/or joint pain (without joint swelling or redness, and may be transitory). Other symptoms include headaches (particularly of a new type, severity, or duration), lymph node pain, sore throats, and abdominal pain (often as a symptom of irritable bowel syndrome). Patients also report bone, eye and testicular pain, nerve pain and painful skin sensitivity. Chest pain has been attributed variously to microvascular disease or cardiomyopathy by researchers, and many patients also report painful tachycardia. A systematic review assessing the studies of chronic pain in CFS found that although the exact prevalence is unknown, it is strongly disabling in patients, but unrelated to depression.
- Neurological/cognitive manifestations: Common occurrences include confusion, forgetfulness, mental fatigue/brain fog, impairment of concentration and short-term memory consolidation, disorientation, difficulty with information processing, categorizing and word retrieval, and perceptual and sensory disturbances (e.g. spatial instability and disorientation and inability to focus vision), ataxia (unsteady and clumsy motion of the limbs or torso), muscle weakness and "twitches". There may also be cognitive or sensory overload (e.g. photophobia and hypersensitivity to noise and/or emotional overload, which may lead to "crash" periods and/or anxiety). A review of research relating to the neuropsychological functioning in CFS was published in 2001 and found that slowed processing speed, impaired working memory and poor learning of information are the most prominent features of cognitive dysfunctioning in patients with CFS, which couldn't be accounted solely by the severity of the depression and anxiety.
- Autonomic manifestations: Common occurrences include orthostatic intolerance, neurally mediated hypotension (NMH), postural orthostatic tachycardia syndrome (POTS), delayed postural hypotension, lightheadedness, extreme pallor, nausea and irritable bowel syndrome, urinary frequency and bladder dysfunction, palpitations with or without cardiac arrhythmias, and exertional dyspnea (perceived difficulty breathing or pain on breathing).
- Neuroendocrine manifestations: Common occurrences include poor temperature control or loss of thermostatic stability, subnormal body temperature and marked daily fluctuation, sweating episodes, recurrent feelings of feverishness and cold extremities, intolerance of extremes of heat and cold, digestive disturbances and/or marked weight change - anorexia or abnormal appetite, loss of adaptability and worsening of symptoms with stress.
- Immune manifestations: Common occurrences include tender lymph nodes, recurrent sore throat, recurrent flu-like symptoms, general malaise, new sensitivities to food and/or medications and/or chemicals (which may complicate treatment). At least one study has confirmed that most CFS patients reduce or cease alcohol intake, mostly due to personal experience of worsening symptoms (although the cause of this is unknown and may not be strictly "immunological" as implied by the symptom list).
Patients report critical reductions in levels of physical activity and are as impaired as persons whose fatigue can be explained by another medical or a psychiatric condition. According to the CDC, studies show that the disability in CFS patients is comparable to some well-known, very severe medical conditions, such as; multiple sclerosis, AIDS, lupus, rheumatoid arthritis, heart disease, end-stage renal disease, chronic obstructive pulmonary disease (COPD) and similar chronic conditions. The severity of symptoms and disability is the same in both genders, and chronic pain is strongly disabling in CFS patients, but despite a common diagnosis the functional capacity of CFS patients varies greatly. While some patients are able to lead a relatively normal life, others are totally bed-bound and unable to care for themselves. A systematic review found that in a synthesis of studies, 42% of patients were employed, 54% were unemployed, 64% reported CFS-related work limitations, 55% were on disability benefits or temporary sick leave, and 19% worked full-time.
Proposed causes and pathophysiologyEdit
The cause of CFS is unknown, although a large number of causes have been proposed. In a basic overview of CFS for health professionals, the CDC states that "After more than 3,000 research studies, there is now abundant scientific evidence that CFS is a real physiological illness." The cause of CFS may be different for different patients, but if so, the various causes may result in a common clinical outcome.
Researchers have found evidence that CFS may involve distinct neurological abnormalities. MRI and SPECT scans show abnormalities within the brain. Studies have shown that CFS patients have abnormalities in blood flow to the brain possibly indicative of viral cause and similar but not identical compared to patients with clinical depression. A number of studies have shown that CFS patients have abnormal levels of neurotransmitters including increased serotonin (the opposite of what is found in primary depression). Reduced brain serotonin receptor sensitivity or number, and high auto antibodies to serotonin have also been found. Recent studies found altered gene expression in the brain’s serotonin and sympathetic nervous system pathways, with altered responses of the HPA axis to serotonin. Other reported neurotransmitter irregularities include glutamate, acetylcholine sensitivity associated increased cutaneous microcirculation, and autoantibodies to cholinergic receptors associated with central pain. Beta-endorphin, a natural pain killer, has been found to be low in CFS patients, the opposite of what is found in primary depression.
Dysautonomia is the disruption of the function of the autonomic nervous system (ANS). The ANS controls many aspects of homeostasis. The dysautonomia that evidences itself in CFS shows up mostly in problems of orthostatic intolerance - the inability to stand up without feeling dizzy, faint, nauseated, etc[How to reference and link to summary or text]. Research into the orthostatic intolerance found in CFS indicates it is very similar to that found in postural orthostatic tachycardia syndrome (POTS)[How to reference and link to summary or text]. POTS and CFS patients exhibit reduced blood flows to the heart upon standing that result in reduced blood flow to the brain. The reduced blood flows to the heart are believed to originate in blood pooling in the lower body upon standing. Many CFS patients report symptoms of orthostatic intolerance and low or lowered blood pressure.
- Inner-ear disorders
- Main article: balance disorder
Problems such as Meniere's, tumor in the inner ear, [How to reference and link to summary or text] or Benign Paroxysmal Positional Vertigo (BPPV) can cause dizziness, vertigo, and fatigue. Recurrent ear infections are common in some CFS sufferers[How to reference and link to summary or text]. Tinnitus is also quite common. Antibodies associated with hearing loss have been found in CFS and FMS patients with inner ear disorders 
- Orthostatic hypotension
Syndromes of orthostatic intolerance, in particular neurally mediated hypotension (NMH) and postural orthostatic tachycardia syndrome (POTS), have been shown to be associated with chronic fatigue syndrome. These conditions, which reduce blood flow to the brain after periods of standing, can be diagnosed with a tilt table test. A clinical trial of fludrocortisone, a drug sometimes used to treat low blood pressure, showed little or no benefit for people with CFS.
There is some overlap in symptoms between depression and CFS, and sometimes cases of CFS are mistakenly attributed to clinical depression. There are, however, many clinical differences between the two.
Clinical depression often responds well to physical exercise, whereas CFS is characterised by exercise intolerance but with a willingness to be active. (See section on post-exertion symptom exacerbation.) Comorbid depression occurs in 10-15% of CFS patients and should be treated as usual, except that the patient’s energy level, cognitive dysfunction and drug sensitivity must be taken into account. Comorbid depression may be a pre-existing condition, or the result of living with CFS.
Stress and traumaEdit
The majority of people who experience stress/trauma do not develop CFS, but these factors (including infection) increase the likelihood of acquiring CFS within one year and a genetic disposition to CFS has been demonstrated. Two studies suggest that self-reported childhood stress/trauma significantly increases the likelihood of acquiring CFS as an adult: A preliminary study found a 3 to 8 fold increase (depending on the trauma type). A study involving participants from the Swedish Twin Registry found that in matched case-control analyses, higher emotional instability and self-reported stress were significant risk factors (odds ratios, 1.72 and 1.64, respectively), while in co-twin control analyses the risk of emotional instability decreased to 1.02 whereas that of stress increased to 5.81 (suggesting genetic influences); there was also no association between extraversion and fatigue. Anxiety disorders have been associated with CFS in 5-15 year olds.
The CDC stated in 2006, their studies found gene mutation and abnormal gene activity levels in CFS patients that relate to the function of the hypothalamus-pituitary-adrenal (HPA) axis, which helps regulate the body's stress response. Earlier CFS research also found evidence that suggested abnormal stress response was associated with subtle dysfunction of the HPA axis. Questions remain about the pathophysiology of these findings. The controversy surrounding CFS has caused some social issues for patients and may contribute to their stress (see the Social issues section).
Oxidative stress is an imbalance between the production of reactive oxygen and a biological system's ability to readily detoxify the reactive intermediates or easily repair the resulting damage. Several studies and a review have implicated oxidative stress in CFS symptoms; especially relating to fatigue, pain and postexertional malaise/exercise intolerance. According to research, the findings on oxidative stress and nitrosative stress (nitric oxide-related toxicity); are associated with an inflammatory response, seem consistent with abnormal 2-5A synthetase/RNase L enzyme (antiviral) activity and involves an immune response, against disrupted lipid membrane components, (by-products of lipid peroxidation ) and to nitric-oxide modified amino acids; related to symptoms and severity in CFS.   Gene expression studies suggest a common link between oxidative stress, immune system dysfunction and potassium imbalance in CFS patients leading to impaired nerve balance strongly reflected in abnormal heart rate variability.
When compared with CFS patients with normal natural killer cell activity, a 2006 study found those with lower levels reported less vigor, more daytime dysfunction, and more cognitive impairment; with the researchers suggesting this to be useful at subtyping. A systematic review on the immunology of CFS (published in 2003) found an inverse association between study quality and findings of low levels of natural killer cells (suggesting that the association may be related to study methodology), although no such association was found with studies finding abnormalities in T cells and cytokine levels. In 2006 an updated review on the phenomenology and pathophysiology of CFS found that, "immune system involvement in the pathogenesis of CFS seems certain but the findings on the specific mechanisms are still inconsistent." There is also evidence that people with CFS have improper gene expression including both over expression and under expression of genes involved in the immune system (see the gene expression section).
RNase L deregulationEdit
Several studies have detected an abnormal form and activity level of 2-5A synthetase/RNase L enzyme (antiviral immune response) in some CFS patients that appears to correlate with a reduction in exercise capacity. A review published in 2005 suggested that this impaired pathway is of clinical importance and that further studies addressing treatment of this deregulation are warranted. A study found that elevated RNase L did not correlate with alpha-delta sleep.
Autoimmune disorders, representing a hyperactive immune system, most likely through a cell-mediated process, have been suggested. In July 2005, researchers in the UK reported significant gene changes in the white blood cells in CFS patients consistent with the theory of immune system activation, possibly by an antigen triggering a constant immune fatigue state. The study, led by Dr Jonathan Kerr, discovered that 35 white blood cell genes, out of a total of 9,522 genes scanned were demonstrating differential function. There was also suggestion of neuronal and mitochondrial dysfunction as a result.
Immunodeficiency disorders (representing an underactive immune system) have been reported. As early as 1989, a study was published in Australia that documented a loss of immunological integrity in one hundred CFS sufferers. The authors reported finding disordered ratios of T-cell subsets and reduced levels of immunoglobulins specifically IgG 1 and IgG 3; these findings corresponded with similar findings in the U.S. among leading researchers. Most strikingly, using the French Multitest to measure the body's response to a variety of antigens, the Australian group found that 33% of the subjects were hypoallergic, meaning they had a reduced immune response to the tested antigens, while an additional 55% were completely anergic (no immune response to the antigens).
Other immunological findingsEdit
- Several studies have implicated a higher level of bioactive transforming growth factor-beta (TGF-beta) in CFS patients.
- A study published in 1995 found that 3 immunological tests (protein A binding, Raji cell, or C3/C4) best discriminated CFS patients from fatigued controls.
- A recent study suggested that CFS may be characterized by an IgM-related immune response directed against disrupted lipid membrane components, by-products of lipid peroxidation, S-farnesyl-L-cysteine, and NO-modified amino-acids, which are normally not detected by the immune system but due to oxidative and nitrosative damage have become immunogenic.
- A study found that while exercise worsened symptoms in CFS patients, it also increased allergen challenge response only in the CFS group, regardless of allergy status.
- Further information: psychoneuroimmunology
A 2006 review published in Current neurovascular research states that there is growing evidence of autoantibodies to neuronal or endothelial (interior surface of blood vessels) targets in psychiatric disorders and hypothesizes how autoantibodies can play a role in the psychiatric disorders present in CFS. Researchers involved in a review examining an immunological basis for CFS concluded that neuropsychiatric symptoms in CFS patients may be more closely related to disordered cytokine production by glial cells within the central nervous system rather than to circulating cytokines. In one study, autoantibodies for muscarinic cholinergic receptor had been found in over half of the CFS patients and seemed to correlate with the severity of the "feeling of muscle weakness". Elevated levels of nitric oxide (not to be confused with nitrous oxide) has been found in some CFS patients. One hypothesis is that elevated levels of nitric oxide may contribute to a "sensitization" of the nervous system that results in behavioral changes.
Often, there is evidence of enteroviruses, e.g. the Coxsackie virus. The type of enterovirus varies, which can affect symptoms. In the times of polio outbreaks, paresis was often found in ME patients; this is no longer the case. Stomach biopsies of 80% of CFS patients showed the presence of enteroviruses in one study, as opposed to only 20% among controls, and nearly all biopsy specimens had microscopic evidence of mild chronic inflammation. Hyde and others suggest that these enteroviruses had been latent to be awakened by another, triggering infection, after which the immune system stays chronically active to combat the enterovirus.
- Epstein-Barr virus
For many years the ubiquitous Epstein-Barr virus, present in 90% of the population, was the principal suspect based on abnormal immunologic responses observed in uncontrolled studies. Subsequent studies using various types of controls have had mixed conclusions.
- Other viruses
Other implicated viruses include cytomegalovirus, and human herpesvirus type-6 (HHV-6). A review by Soto and Straus in 2000 states the evidence argues against an ongoing active herpes virus infection.
- HPA Axis
The HPA axis controls levels of hormones such as cortisol in the body. It is activated in a circadian (daily) cycle and modulated by stress, digestion, illness and other factors, and is important in regulating energy metabolism, the immune system, stress responses and inflammation in the body.
The HPA axis has been much studied in CFS which has shown underactivation with low cortisol not caused by adrenal insufficiency.    These results have not been replicated in all CFS patients, so it is not clear whether this is just a subset of patients. It is also not clear if the HPA axis abnormalities are a cause or a result of the illness. However, a review has concluded, that even if the HPA axis dysfunctions are secondary to other factors; they are a likely factor in symptom propagation in CFS. 
Gene expression is the process by which the inheritable information in a gene, such as the DNA sequence, is made into a functional gene product, such as protein or RNA. Research into CFS has found abnormalities in gene expression, and the CDC has conducted over twenty related studies itself.  It has been found that patients with CFS have specific abnormalities in expression of multiple genes which are involved in the biological process of transport (both vesicle-mediated and protein transport) and this became accentuated when CFS patients exercise. Another study found that "the differentially expressed genes imply fundamental metabolic perturbations", such as those involved in purine and pyrimidine metabolism, glycolysis, oxidative phosphorylation, and glucose metabolism. Several other studies have also suggested a genetic component to CFS involving immune dysfunction; T cell activation, perturbation of neuronal and mitochondrial function, possible links to organophosphate exposure and virus infection; immune response, apoptosis, ion channel activity, signal transduction, cell-cell signaling, regulation of cell growth and neuronal activity; some of which may be treatable with drugs that are already available. Gene expression abnormalities have been found relating to the central nervous system, metabolism and immune system; and has been associated by the CDC with impaired response to physical and psychological stresses in people with CFS.  Linking genes to specific symptoms has been difficult, although is likely to be an important means to elucidate the pathogenesis of CFS.Seven subtypes of CFS/ME patients with distinct clinical differences have been identied in one gene expression study.
Polymorphism in biology occurs when two or more clearly different types exist in the same population of the same species. Preliminary studies have suggested that the risk of developing CFS may be influenced by polymorphisms in genes affecting the central nervous,  endocrine, immune, and/or cardiovascular systems. A review published in 2007 stated that certain genetic polymorphisms might be regarded as predisposing factors.
Metabolic disorders such as McArdle disease, CPT II deficiency, myoadenylate deaminase deficiency, and mitochondrial disorders can cause symptoms that strongly resemble CFS[How to reference and link to summary or text]. Mitochondrial disturbances have been discovered in patients diagnosed with postviral fatigue syndrome. 
Other findings regarding CFS in general include:
- A large study found that higher levels of exercise in childhood is associated with a lower risk of developing CFS later on. It also found that the development of CFS was not associated with other childhood or maternal factors such as psychological problems, academic ability, allergic tendencies, birth weight, birth order or obesity.
- Researchers compared 48 CFS patients with 29 controls and found that 10 of the CFS patients tested positive for enterovirus RNA (most closely to that of the coxsackie B virus) in their muscles while all of the 29 controls tested negative. 28 of the 48 CFS patients had an abnormal lactate response to exercise, including 9 of the 10 who tested positive for enterovirus RNA.
- A study found that fatigue persists in a significant minority of patients for six months or more after infections, suggesting post-infective fatigue syndrome is a valid illness model for investigating CFS.
- In a study on people who had glandular fever (which is caused by the Epstein-Barr virus), no difference was found between the levels of virus in the blood from patients who recovered quickly when compared with those whose fatigue lasted more than six months, although the latter had an altered immune response. The scientists involved believed this suggests CFS can be caused by neurological damage done (during the acute infection phase) to parts of the brain which control perception of fatigue and pain.
- Abnormal lactic acid responses to exercise in some CFS patients, has been suggested to be a factor in CFS because it is commonly believed to be responsible for muscle fatigue. However, some scientists have found that lactic acid may actually help prevent muscle fatigue rather than cause it, by keeping muscles properly responding to nerve signals.
- Essential fatty acid levels: Several studies published between 1990 a 2005 reported finding reduced levels of Omega-6 or Omega-3 essential fatty acids in cell membranes or serum in patients diagnosed with postviral fatigue syndrome or CDC defined CFS. One study conducted in 1999 on Oxford criteria defined CFS patients (Warren et al.) found no significant differences in fatty acid levels between treatment and placebo groups. There have also been two controlled systematic proton neurospectroscopy studies of CFS patients that found raised levels of choline in brain areas consistent with an abnormality of essential fatty acid and phospholipid metabolism in the brain in CFS patients. These changes have been considered due to essential fatty acid deficiencies resulting from delta 6 desaturase (D6D) enzyme inhibition in CFS. Some researchers have suggested D6D inhibition is linked to a possible viral cause. 
- Carnitine deficiency; is said to produce symptoms of fatigue and myalgia similar to PVFS, ME and CFS.    Several studies have reported finding carnitine abnormalities in CFS patients. including lower serum total carnitine, free carnitine and acylcarnitine levels. The findings of reduced brain uptake of acetylcarnitine suggest that the levels of biosynthesis of neurotransmitters through acetylcarnitine might be reduced in some brain regions of CFS patients. There has been a contradictory study that included Oxford criteria defined patients. Others report of finding reduced levels of carnitine together with reduced essential fatty acids in patients with CDC defined CFS.
- Researchers have found that children and teenagers with CFS are several times more likely to have some hyperflexible joints in an association with Ehlers-Danlos syndrome.
At this time, there is no accepted conclusive test or series of tests of chronic fatigue syndrome. CFS is therefore largely an exclusionary diagnosis. If a doctor suspects a patient may have CFS they should begin the diagnostic process by eliminating other potential causes of the patient's symptoms, as "chronic fatigue" and related symptoms can be caused by a wide variety of conditions which should be investigated and managed.
CDC 1994 criteriaEdit
- Primary symptom
Clinically evaluated, unexplained, persistent or relapsing chronic fatigue that is:
- of new or definite onset (has not been lifelong);
- is not the result of ongoing exertion;
- is not substantially alleviated by rest;
- and results in substantial reduction in previous levels of occupational, educational, social, or personal activities.
- Additional requirement
The concurrent occurrence of four or more of the following symptoms, all of which must have persisted or recurred during 6 or more consecutive months of illness and must not have predated the fatigue:
- self-reported impairment in short-term memory or concentration severe enough to cause substantial reduction in previous levels of occupational, educational, social, or personal activities;
- sore throat;
- tender cervical or axillary lymph nodes;
- muscle pain;
- multi-joint pain without joint swelling or redness;
- headaches of a new type, pattern, or severity;
- unrefreshing sleep;
- post-exertional malaise lasting more than 24 hours.
- Final requirement
All other known causes of chronic fatigue must have been ruled out, specifically clinical depression, side effects of medication, eating disorders and substance abuse.
The clinical evaluation should include:
- A thorough history that covers medical and psychosocial circumstances at the onset of fatigue; depression or other psychiatric disorders; episodes of medically unexplained symptoms; alcohol or other substance abuse; and current use of prescription and over-the-counter medications and food supplements.
- A mental status examination to identify abnormalities in mood, intellectual function, memory, and personality. Particular attention should be directed toward current symptoms of depression or anxiety, self-destructive thoughts, and observable signs such as psychomotor retardation. Evidence of a psychiatric or neurologic disorder requires that an appropriate psychiatric, psychological, or neurologic evaluation be done.
- A thorough physical examination.
- A minimum battery of laboratory screening tests including complete blood count with leukocyte differential; erythrocyte sedimentation rate; serum levels of alanine aminotransferase, total protein, albumin, globulin, alkaline phosphatase, calcium, phosphorus, glucose, blood urea nitrogen, electrolytes, and creatinine; determination of thyroid-stimulating hormone; and urinalysis.
According to Fukuda e.a., other tests have no known value, unless indicated on an individual basis to confirm or exclude a differential diagnosis, such as multiple sclerosis.
NICE (UK) 2007 criteriaEdit
The UK National Institute for Health and Clinical Excellence (NICE), published a multidisciplinary clinical practice guideline in 2007 in which the following criteria are employed:
- fatigue that is new, persistent and/or recurrent, not explained by other conditions and has resulted in a substantial reduction in activity level characterised by post-exertional malaise and/or fatigue (typically delayed, for example by at least 24 hours, with slow recovery over several days) and
- one or more of the following list of symptoms: difficulty with sleeping, muscle and/or joint pain at multiple sites without evidence of inflammation, headaches, painful lymph nodes that are not pathologically enlarged, sore throat, cognitive dysfunction, worsening of symptoms by physical or mental exertion, general malaise, dizziness and/or nausea and palpitations with no identifiable heart problem.
The diagnosis should be reconsidered if none of the following symptoms remain: post-exertional fatigue or malaise, cognitive difficulties, sleep disturbance, chronic pain.
The guideline requires fatigue to have been present for 4 months in an adult or 3 months in a child. It expects a diagnosis in a child to be made by a pediatrician. There are no recommendations on who is to make the diagnosis in an adult. The guideline states that a referral to a ME/CFS specialist should be offered immediately to the severely ill.
The NICE criteria have been criticized by patients' associations for being far too relaxed and ignoring the WHO classification of CFS/ME as a neurological condition.
Other scoring systems have also been proposed to quantify CFS symptoms for research purposes. These include:
- Holmes et al (1988) scoring system. Also sometimes called "CDC 1988," to distinguish from the newer CDC system.
- Oxford criteria (1991)
- Carruthers et al (2003) Canadian Case definition for ME/CFS
- Australian Guidelines (2004)
Issues with the definitions/criteriaEdit
- Selection bias and inconsistencies
Several studies have found that using different case definitions ( eg broad vs conservative ) has major influence on the types of patients selected and have also supported the distinction between specific subgroups of CFS to be identified and/or for the case definition to be further clarified with emphasis on using empirical studies: An international CFS study group for the CDC found ambiguities in the CDC 1994 CFS research case definition which contribute to inconsistent case identification. Researchers have found that a difference in the self-reported cause of a patient's CFS is associated with significant differences in clinical measures and outcomes, and concluded it is likely that their response to treatment may vary and the CFS definition should be improved to define more homogeneous groups of patients for the purposes of research and treatment. It also may be inappropriate to synthesize results from CFS studies that use different definitions to select study populations. It has been found that identification of new diagnostic symptoms, the use of severity ratings for symptomatology, and the identification of standardized measures that differentiate cases of CFS from other conditions; all hold promise for improving the sensitivity, specificity, and reliability of the diagnostic criteria for CFS.
- Improving accuracy
A study found that the best predictors for people accurately fitting the CDC 1994 definition of CFS were the presence of postexertional malaise, unrefreshing sleep, and impaired memory-concentration, and this accuracy increased when severity of these symptoms were taken into account. Another examination of the CDC's working case definition(s) of CFS found that the differential accuracy is strengthened when eliminating three symptoms (muscle weakness, joint pain, sleep disturbance) and adding two others (anorexia, nausea). It has also been found that the Canadian 2003 definition (a less used but stricter criteria) selects cases with less psychiatric co-morbidity, more physical functional impairment, and more fatigue/weakness, neuropsychiatric, and neurological symptoms.
- Possible subtypes
Studies suggest the existence of CFS subtypes. After examining the 'minor' diagnostic symptoms of CFS in women meeting the CDC 1994 criteria, researchers found that 3 subtypes could be identified; musculoskeletal, infectious and neurological; with associated impairment characteristic of each subtype. "Extreme scores" characterized about 2/3 of the sample, with higher disability in those with the highest scores. Depression and anxiety were not more prevalent in any particular subtype, and did not increase with the severity of specific symptom reports.
- Diagnosis inaccuracies
A review published in 2006 found that the accurate diagnosis of CFS is low and another study found that physicians have a tendency to underrecognize psychiatric illness, especially when assessing patients whose chronic fatigue is fully explainable by a psychiatric disorder and who may be misdiagnosed with CFS.
- Terminology implications
Because of the similarity in terminology, CFS is often confused with "chronic fatigue". Fatigue in the perceived absence of disease has traditionally been seen within the purview of psychiatry. A study found that while most medical trainees consider the symptom complex of CFS to be a serious illness resulting in poor quality of life, the "chronic fatigue syndrome" name may be regarded less seriously than the "myalgic encephalopathy" name. Another study found that nurses and physician assistants viewed a patient's CFS symptoms as more severe and disabling if they were told the patient had a more medical sounding diagnosis of "chronic neuroendocrineimmune dysfunction syndrome".
There is no generally accepted diagnostic test to reliably diagnose or exclude chronic fatigue syndrome. Research has not identified an association between CFS and one particular virus.
- Complete blood count
- Blood chemistry (electrolytes, glucose, renal function, liver enzymes, protein levels and calcium)
- Thyroid function tests
- Erythrocyte sedimentation rate (ESR)
- Urinalysis for blood cells, protein and glucose
The 2007 UK NICE guideline includes, in addition to the CDC panel: C-reactive protein (a marker of inflammation), creatine kinase (a muscle-related enzyme), plasma viscosity (optional if ESR done) and serology for celiac disease. Ferritin determination may be performed in children and young people, and in adults only if other tests suggest iron deficiency. The guideline recommends clinical judgement in decisions to perform other tests in addition to the standard set. Testing for infections (e.g. Lyme disease, viral hepatitis, HIV, mononucleosis, toxoplasmosis or cytomegalovirus) is only recommended if the patient gives a specific history for this. Routine performance of the head-up tilt test, auditory brainstem responses and electrodermal conductivity is discouraged.
In contrast, the Nightingale Research Foundation recommends extensive testing including brain imaging and tests for neuropsychological, sleep, muscle, vascular and cardiac dysfunction to diagnose ME/CFS.
Suhadolnik, DeMeirleir e.a. developed a test to measure the fragmentation of the enzyme RNAse L. This fragmentation was found to be significant in CFS and has some use as a marker, but the test has limited availability.
Historically, many doctors have been unfamiliar with CFS, and some have refused to diagnose it. Others minimised the seriousness of CFS. This situation is changing somewhat, with more doctors willing to diagnose it. In the UK, the 2002 Chief Medical Officer's report stated that all doctors should consider CFS as a serious chronic illness — and treat patients accordingly. Similar progress has been made in the United States.
There remains considerable skepticism amongst some medical professionals about the existence of CFS as a "real" — i.e. medical as opposed to behavioral — condition, possibly due to the extreme uncertainty of its etiology, and the lack of testing for biomedical signs and its largely exclusionary definition. Many people are inclined to believe that a condition with few or no specific biomedical markers may be psychological in origin. This had led to a frustration in many patients, who feel that their disability is not psychological, but biological, and point to the epidemic history and biomedical research trends. Some patients' groups and experts state that research into CFS (ME) in the UK has been mostly hijacked by a "lobby of psychologists and psychiatrists",, who they claim hold significant power within the medical fraternity, with a resultant "gross abuse/neglect of patients." The UK and the Netherlands have particularly seen disagreements between biomedical researchers and their adherents, and psychiatrists (particularly proponents of cognitive behavioral therapy, or CBT) and supporters of the theory that CFS is psychological in origin, and can be "cured" or "rehabilitated" by psychotherapy and exercise.
Many patients do not fully recover from CFS, even with treatment. Some management strategies are suggested to reduce the consequences of having CFS. A sytematic review has shown that CFS patients are less susceptible to placebo effects than predicted, and have a low placebo response compared to patients with other diseases.
Behavioral interventions including cognitive behavioral therapy (CBT) and graded exercise therapy (GET) have been shown to be at least partially effective in some people with CFS. A systematic review published in the Journal of the Royal Society of Medicine (October 2006) found these are the only two known treatments that seem helpful. The statement of principal findings regarding CBT/GET was: "A number of RCTs (randomised controlled trials) suggest that behavioural interventions, including elements of CBT, GET and rehabilitation, may reduce symptoms and improve physical functioning of people with CFS/ME." However some uncertainty still exists over the efficacy of these treatments, especially GET for severely affected patients, as none were included in studies that passed the inclusion criteria of the review. The review also emphasized the need for more and better conducted studies of both therapies, as well as more research into the adverse affects of treatments in general as they may be under reported or poorly quantified. As mentioned in the review under the 'unanswered questions/further research' section, very few studies assessed the effectiveness of "interventions for children and young people and for severely affected patients." More research is needed on severely affected patients in general; because many treatments and studies require patients to attend a clinic, and those with the worst symptoms often receive the least support from health and social services. The authors also expressed concern about possible bias in the CFS literature, a lack of uniformity in case definitions and study inclusion/exclusion criteria (studies using any CFS criteria were included), and the basic information provided about the participants; which they state makes it difficult to assess the generalizability of the findings of many of these studies. This review found that no intervention had been proved effective in restoring the ability to work. An earlier systematic review published in 2002 also found this, although CBT was "lending a possible association between improvement in the ability to work and an increase in the number of patients employed". This earlier review also found that no specific patient characteristics seemed to serve as best predictors of positive employment outcomes in CFS patients, although did find that depression of greater severity was associated with unemployment. However, another systematic review published in 2004 concluded "Only cognitive behavior therapy, rehabilitation, and exercise therapy interventions were associated with restoring the ability to work."
The "Gibson Report" (Report of the Group on Scientific Research into Myalgic Encephalomyelitis 2006), a political inquiry into the science of CFS provides information about treating CFS with CBT and/or GET. However, the report has been criticised by the ME Association, for: being poorly conducted, misrepresentations, omissions, lack of references, factual inaccuracies or bias, and even potentially damaging implications. The "25% ME Group", a UK advocacy support group for severely affected M.E. sufferers, state, in their submission to the Gibson report, that both CBT and GET are unhelpful and may be dangerous/harmful to severely affected CFS patients. The discrepancy between trial results and patient group surveys has been noted by the P.A.C.E. trial group, who are conducting a larger more detailed study into CBT and GET which is currently underway and is due for completion in 2009.
Cognitive Behavioral Therapy (CBT)Edit
Results from clinical studies have suggested that cognitive behavioral therapy (CBT) is an effective, evidence-based therapy for CFS. The use of psychological therapies such as CBT does not imply that CFS is a psychiatric condition or that physical symptoms are not real. Some CFS patients have comorbid depression and/or anxiety. In addition, it is arguedTemplate:Who? that CBT may teach patients various "coping strategies" to help them deal with cognitive impairments such as a deterioration of short-term memory or abbreviated attention span[How to reference and link to summary or text], although it is uncertain how changing one's schemas, as CBT theory contends, would cause improvement in these serious pathological symptoms[How to reference and link to summary or text]. Dr. David Smith, a former medical advisor to the ME Association in the UK who reports to have successfully treated many children using antidepressants and therapy, offers a possible explanation on his website. Some patients and patient groups[attribution needed] state that this is innaccurate, arguing that CBT is described as an "exposure therapy" e.g. UK mental health charity MIND, that most of the conditions commonly listed as being suitable for CBT are behavioural and that the 2002 UK CMO's Report describes CBT as "a tool for constructively modifying attitude and behaviour." Carruthers and Van de Sande in their Overview of the Canadian Consensus Guidelines, note that to supportive counselling should not be mis-termed CBT to avoid patient confusion between the two treatments.
The Gibson Report  states that CBT in general is helpful to many people with other illnesses; and while it is controversial in regards to CFS, it seems to be most effective in those with less severe forms but much less effective in the severely affected. Commenting on the relevance of CBT for CFS, the report states that it has a role to play in treatment but at best is only a partial answer and more research is needed. A systematic review on CBT finds that "CBT was associated with a significant positive effect on fatigue, symptoms, physical functioning and school attendance." The reviewers state that the quality of many recent trails on CBT are lower quality randomized controlled trials or trials that did not involve random allocation. The reviewers also state that one recent, good quality trial of CBT in children and adolscence supports the effectiveness of CBT. The reviewers state that reasons for withdrawals typically remain unreported, and that a degree of publication bias seems to be present in CFS/ME literature as a whole. In one study, the effect of CBT has been demonstrated up to five years after therapy. A large evaluation study in Belgium, however, lead to the conclusion that while on average CBT may cause patients to feel somewhat better, objective measurement shows no reduction in their disability[verification needed]. Another recent study found that CBT improved self-reported cognitive impairment but not actual neuropsychological test performance. According to researchers of one study, CBT usually aims at reducing fatigue but can also reduce pain, although higher pain at baseline was associated with a negative treatment outcome. The place of CBT for children, young people and the severely affected needs to be better established, although some open studies suggest that it is helpful, so long as it is adapted for the individual patient[How to reference and link to summary or text].
Many CFS patients face the stress of economic and legal problems. CFS sufferers may lose jobs, marriages, and the ability to work at all, causing severe financial loss and distress. A lawyer, social worker, or counsellor can be beneficial in helping the patient determine their best course, and may assist the patient with applying for work-related disability, social programs, and other aid. A study which included 45 CFS patients found that psychodynamic counselling has comparable effectiveness to cognitive behavioral therapy (CBT) in the treatment of chronic fatigue.
Graded Exercise Therapy (GE, GA or GET)Edit
Several rehabilitation programs have been proposed which involve supervised or self-monitored graded exercise or activity. [How to reference and link to summary or text] Such programs are designed to overcome deconditioning, increase strength and cardiovascular health. [How to reference and link to summary or text] The program should incorporate considerable education wherein the sufferer learns to start at an appropriate level of activity (based upon intensity and duration) which is incrementally increased, at a rate which does not substantially increase symptoms. [How to reference and link to summary or text]
The Gibson Report states GET is one of the most common treatments for CFS in the UK. Dr. Peter White found that in four studies 50-70% of patients improved with GET, and he stated that GET (combined with CBT) has only been shown to be efficacious in small trials. The Gibson Report mentions the 25% ME Group statement that, "only 5% of their members found GET helpful and 95% found it unhelpful". Many patients who submitted personal evidence to the Gibson inquiry said that they had similarly negative experiences which they attributed to their participation in GET. The authors of the report expressed concern about GET treatment guidelines, arguing that there are be potential risks of GET for CFS patients, "Some of our evidence suggests that GET carries some risk and patients should be advised of this." The authors stated that the CFS guidlines lacked cautions about these possible risks and they said that patients should consider of checking for heart trouble before attempting GET. The authors said that the perception that GET may make severe sufferers feel worse "has lent fuel to their often serious antipathy to the doctors offering it." A New Zealand study suggests that GET may result in self-reported improvement by reducing the degree to which patients focus on their symptoms.
Antidepressants are often prescribed to CFS patients. Their purpose can be to treat secondary depression or mood swings, but low dosage tricyclic antidepressants are sometimes prescribed to improve sleep quality and reduce pain.. However, antidepressants often have side effects, some of which can increase CFS symptoms, and baseline metabolism differs between patients. Finding antidepressants, if any, that help the individual patient, is therefore a matter of trial and error.
Overall, studies into the use of antidepressants in CFS have had mixed results. Some studies have shown a reduction in symptoms with antidepressant use, while others have shown no benefit.
Autonomic nervous system stimulantsEdit
Drugs such as atomoxetine (Strattera®), which stimulate the autonomic nervous system, appear to have positive effects in some people with CFS symptoms. Amphetamines and amphetamine analogs may help some patients. For example, methylphenidate (Ritalin®) has been found to be significantly better than placebo in relieving fatigue and concentration disturbances in a minority of CFS patients but more research is needed into the long term effects. Modafinil (Provigil®), a medication designed to aid in maintaining wakefulness, has had some positive effect on individuals with CFS, but has not been properly studied. A small study suggested that long-term treatment with modafinil may not be beneficial for CFS patients.
Various hormones have been tried from time to time, including specifically steroids (such as cortisol) and thyroid hormones. Though conventional steroidal treatment may produce short-term pain relief, it has not been shown to be of any general benefit. Studies performed by Dr. Jacob Teitelbaum incorporating low-dose cortisol therapy have demonstrated positive results, but other studies have shown little benefit from cortisol itself[How to reference and link to summary or text].
Other medical treatmentsEdit
Allergy identification and treatmentEdit
In cases where CFS-like symptoms may be caused by allergies, enzyme deficiencies or food intolerance, such as chronic sinusitis   , coeliac disease, or irritable bowel syndrome, allergy testing, treatments, or elimination diets may prove beneficial. 
Complementary and alternative medicineEdit
Essential fatty acid treatmentsEdit
Behan and Horrobin in a 1990 study of individuals diagnosed with postviral fatigue syndrome stated patients given essential fatty acids reported much greater symptom improvement verses patients given placebo. A fatty acid supplementation study conducted in 1999 using patients diagnosed by the Oxford criteria (Warren et al.) declared there were no significant differences between treatment and placebo groups. A review of CFS treatments by Reid et al. in 2000, concluded the Behan and Warren studies showed mixed results, and classified dietary supplements as "unknown effectiveness".
One small randomised controlled trial compared intramuscular injections with magnesium sulphate to placebo. The study stated greater improvement was found in the treatment group compared to the control group, as measured by the Nottingham health profile. The previously noted review by Reid et al. determined subsequent studies have failed to find a deficiency of magnesium in people with chronic fatigue syndrome, and classified magnesium treatments in dietary supplements having "unknown effectiveness".
Complementary and alternative medicine usageEdit
Two studies reported increased utilization of alternative treatments by people with CFS vs. without. In one study designed to assess use of alternative medicines and perceived benefits with 63 paired CFS and non-CFS co-twins, 91% of twins with CFS and 71% without CFS used at last one alternative treatment in their life, and a large proportion of all twins considered them helpful. Future research should ascertain the usefulness of alternative practices in the management of CFS.
A systematic review of 14 studies of the outcome of untreated people with CFS found that "the median full recovery rate was 5% (range 0–31%) and the median proportion of patients who improved during follow-up was 39.5% (range 8–63%). Return to work at follow-up ranged from 8 to 30% in the three studies that considered this outcome." .... "In five studies, a worsening of symptoms during the period of follow-up was reported in between 5 and 20% of patients." It is not known whether any patients truly "recover" entirely from the illness, or achieve remission from a relapsing, remitting illness[How to reference and link to summary or text]. Few untreated patients report a total "cure".
CFS is unlikely to increase the risk of an early death. A systematic review of 14 studies of the outcome of CFS reported 8 deaths, but none were considered directly attributable to CFS. To date there have been two studies directly addressing life expectancy in CFS. In a preliminary 2006 study of CFS self-help group members, it was reported that CFS patients were likely to die at a younger than average age for cancer, heart failure, and suicide. However, a much larger study of 641 CDC criteria diagnosed patients with CFS, who were followed up for a mean of 9 years, showed no excess risk of dying from any cause.
People diagnosed with CFS may die, as in the case in the UK of Sophia Mirza, where the coroner recorded a verdict of "Acute anuric renal failure due to dehydration arising as a result of CFS." According to Sophia's mother, Sophia became intolerant to water and managed only 4 fluid ounces per day. The pathologist said, "ME describes inflammation of the spinal cord and muscles. My work supports the inflammation theory...The changes of dorsal root ganglionitis seen in 75% of Sophia's spinal cord were very similar to that seen during active infection by herpes viruses." This was seen as a form of recognition by the patients' community. Previous cases have listed CFS as the cause of death in the US and Australia
Due to problems with the definition of CFS, estimates of its prevalence vary widely. Studies in the United States have previously found between 75 and 420 cases of CFS for every 100,000 adults. The CDC states that more than 1 million Americans have CFS and approximately 80% of the cases are undiagnosed. All ethnic and racial groups appear susceptible to the illness, and lower income groups are slightly more likely to develop CFS. More women than men get CFS — between 60 and 85% of cases are women; however, there is some indication that the prevalence among men is under reported. The illness is reported to occur more frequently in people between the ages of 40 and 59. Blood relatives of people who have CFS appear to be more predisposed. However, CFS does not appear directly contagious; caretakers, partners and others in close contact with persons with CFS for years do not develop CFS any more frequently (excluding relatives, as earlier).
Epidemiological research on children and adolescents has received minimal focus according to a 2006 research review. Among minors, prevalence appears to be lower than for adults and various studies have found a range of 50-80% of the cases occur in girls. The authors hypothesize the differences in estimates of ME/CFS among pediatric studies may result because of the lack of a reliable pediatric case definition.
CFS generally occurs in endemic cases. In addition, over 50 instances have been documented, such as the Royal Free Hospital incident, where epidemic clusters were reported.Template:Weasel word In these instances, significant numbers of people came down with illnesses describedTemplate:Weasel-inline as ME or CFS simultaneously, confined to a local area or even a single building. An infectious origin for these clusters has not been established. According to the CDC, CFS itself is not contagious.
Some diseases show a considerable overlap with CFS. According to an article in American Family Physician in 2002, Multiple Sclerosis, Thyroid disorders, anemia, and diabetes are but a few of the diseases that must be ruled out if the patient presents with appropriate symptoms.
People with fibromyalgia (FM, or Fibromyalgia Syndrome, FMS) have muscle pain and sleep disturbances. Fatigue and muscle pain occurs frequently in the initial phase of various hereditary muscle disorders and in several autoimmune, endocrine and metabolic syndromes; and are frequently labelled as CFS or fibromyalgia in the absence of obvious biochemical/metabolic abnormalities and neurological symptoms. Those with multiple chemical sensitivities (MCS) are sensitive to chemicals and have sleep disturbances. Many veterans with Gulf War syndrome (GWS) have symptoms almost identical to CFS. One study found several parallels when relating the symptoms of Post-polio syndrome with CFS, and postulates a possible common pathophysiology for the illnesses.
Although post-Lyme syndrome and CFS share many features/symptoms, a study found that patients of the former experience more cognitive impairment and the patients of the latter experience more flu-like symptoms.
One review (2006) found that there was a lack of literature to establish the discriminant validity of undifferentiated somatoform disorder from CFS. The author stated that there is a need for proponents of chronic fatigue syndrome to distinguish it from undifferentiated somatoform disorder. The author also mentioned that the experience of fatigue as exclusively physical and not mental is captured by the definition of somatoform disorder but not CFS. Hysterical diagnoses are not merely diagnoses of exclusion but require criteria to be met on the positive grounds of both primary and secondary gain.  Primary Depression can be excluded in the differential diagnosis due to the absence of anhedonia and la belle indifference, the variability (lability) of mood, and the presence of sensory phenomena and somatic signs such as ataxia, myclonus and most importantly, exercise intolerance with paresis, malaise and general deterioration<includeonly>[[Category:Pages with broken references]]</includeonly><span class="citeerror">Cite error: Closing </ref> missing for <ref> tag.</span>, which can in some cases become a comorbid situational depression.
Many CFS patients will also have, or appear to have, other medical problems or related diagnoses. Co-morbid fibromyalgia is common, although there are differences in pain complaints. Fibromyalgia will occur in a large percentage of CFS patients between onset and the second year, and some researchers suggest that fibromyalgia and CFS are related. Similarly, multiple chemical sensitivity (MCS) is reported by many CFS patients, and it is speculated that these similar conditions may be related by some underlying mechanism, such as elevated nitric oxide/peroxynitrite. As previously mentioned, many CFS sufferers also experience symptoms of irritable bowel syndrome, temporomandibular joint pain, headache including migraines, and other forms of myalgia. Clinical depression and anxiety are also commonly co-morbid. Compared with the non-fatigued population, male CFS patients are more likely to experience chronic pelvic pain syndrome (CP/CPPS), and female CFS patients are also more likely to experience chronic pelvic pain. CFS is significantly more common in women with endometriosis compared with women in the general USA population.
Many patients find that a chronic fatigue syndrome diagnosis carries a considerable stigma, and has frequently been viewed as malingering, hypochondriac, phobic, "wanting attention" or "yuppie flu". As there is no objective test for the condition at this time, it has been argued that it is easy to invent or feign CFS-like symptoms for financial, social, or emotional benefits. CFS sufferers argue in turn that the perceived "benefits" are hardly as generous as some may believe, and that CFS patients would greatly prefer to be healthy and independent. A study found that CFS patients endure a heavy psychosocial burden. 2,338 respondents of a survey by a UK patient organization highlights that those with the worst symptoms often receive the least support from health and social services. A study found that CFS patients receive worse social support than disease-free cancer patients or healthy controls, which may perpetuate fatigue severity and functional impairment in CFS. A survey by the Thymes Trust found that children with CFS often state that they struggle for recognition of their needs and/or they feel bullied by medical and educational professionals. The ambiguity of the status of CFS as a medical condition may cause higher perceived stigma. A study suggests that while there are no gender differences in CFS symptoms, men and women have different perceptions of their illness and are treated differently by the medical profession. Anxiety and depression often result from the emotional, social and financial crises caused by CFS. While few studies have been made, it is believed that CFS patients are at a high risk of suicide.
A lack of information and awareness has led to many patients to feel stigmatized. CFS patients may not receive total medical and social acceptance and they state that some people trivialise the illness. When the illness is coupled with unaccommodating family, friends, colleagues, often due to stigma, and social repercussions such as financial needs, housing problems, the struggle to obtain disability benefits or insurance, discrimination and misconception within the care sector, it can put demands on the sufferer exceeding their safe capabilities.[How to reference and link to summary or text] Many sufferers say that they need to do things for themselves during the time in which they feel better as there is no-one to delegate these tasks to.
In the 19th century, neurologist George Miller Beard popularised the concept of neurasthenia, in which symptoms included; fatigue, anxiety, headache, impotence, neuralgia and depression. This concept remained popular until well into the 20th century, although by then this diagnosis was viewed as primarily behavioural rather than physical, and to exclude postviral syndromes. It has largely been abandoned as a medical diagnosis.
In 1938 Gilliam made a detailed description of an illness that resembled poliomyelitis, interviewing patients and reviewing records of one of several clusters which had occurred in Los Angeles, United States in 1934. His common "atypical poliomyelitis" features of rapid muscle weakness, vasomotor instability, clonic twitches and cramps, ataxia, severe pain usually aggravated by exercise, neck and back stiffness, menstrual disturbance and dominant sensory involvement et cetera, constituted a twenty-point definition which was later viewed as the first recognisable description of ME. In the 1950s, the British public eye was caught by several outbreaks of a polio'-resembling illness and by now several tens of epidemics had occurred worldwide, including those in Iceland, Norway and New Zealand. Afterwards, it was established that the disorder was primarily found among the general population and the epidemic form was the exception[How to reference and link to summary or text]. Autopsy findings, both on monkeys and on the rare human casualties, led to the conclusion that the disorder was caused by inflammation of the brain and the spinal cord, particularly the afferent nerve roots, and in 1956 it was named accordingly as myalgic encephalomyelitis, reflecting a presumed neuroimmune etiology.
Although non-epidemic cases were recognised, the disorder was in 1970 dismissed as mass hysteria by two psychiatrists. They were criticizedTemplate:Who? for not adequately investigating the patients they described. In a 1978 symposium held at the Royal Society of Medicine (RSM) where there was clear agreement that ME is a distinct disease entity, and new pathology findings were discussed.
The illness gained national attention in the United States when the popular magazine Hippocrates ran a cover story of an epidemic in the mid-1980s at Lake Tahoe, Nevada. The designation Chronic Epstein-Barr Virus was in use in the U.S., but the magazine used the term "Raggedy Ann Syndrome" to note the fatigue and loss of muscle power patients felt.
After investigating the Lake Tahoe cluster, Centers for Disease Control & Prevention researchers attached a different kind of name to the phenomenon: chronic fatigue syndrome, involving some of the symptoms rather than disease taxonomy. They published the first working case definition for CFS in 1988. Research increased considerably, and more so after the criteria were relaxed in 1994.
In the United Kingdom, the Chief Medical Officer Kenneth Calman requested a report from the medical Royal Colleges in 1996. This led to the publication of a joint report in which the term "chronic fatigue syndrome" was found to be most representative. This was followed in 2002 by a further report by the new CMO, Liam Donaldson.
Since its introduction into the eighth edition of the International Classification of Diseases in 1969, CFS/ME has been classified as a disease of the central nervous system. In the ICD-10, ME is the only disorder listed in the tabular classification under G93.3, post-viral fatigue syndrome (PVFS). In 1993 the term "chronic fatigue syndrome" (CFS) was added to the alphabetic list of the classification with the same designation.
Two contrasting viewpoints among ME/CFS experts have become apparent. In a letter to the Lancet, psychiatrists David and Wessely contested the WHO classification, arguing that CFS was a form of neurasthenia to be classified as a psychiatric condition. Dutch researchers tested a model where behavioral, cognitive, and affective factors played a role in perpetuating fatigue, and concluded that this was the correct model for CFS. This result could, however, not be replicated in a population-based study, where fatigue in psychiatric disorders, but not in CFS, proved to be a match.
- ↑ 1.0 1.1 Jason LA, Richman JA, Rademaker AW, Jordan KM, Plioplys AV, Taylor RR, McCready W, Huang CF, Plioplys S (1999). A community-based study of chronic fatigue syndrome. Arch. Intern. Med. 159 (18): 2129-37.
- ↑ Gallagher AM, Thomas JM, Hamilton WT, White PD. Incidence of fatigue symptoms and diagnoses presenting in UK primary care from 1990 to 2001. J R Soc Med 2004;97:571-5. PMID 15574853.
- ↑ 3.0 3.1 3.2 Chronic Fatigue Syndrome Who's at risk?. (htm) Centers for Disease Control and Prevention. URL accessed on 2008-02-07.
- ↑ 4.0 4.1 Jason LA, Jordan K, Miike T, Bell DS, Lapp C, Torres-Harding S, Rowe K, Gurwitt A, De Meirleir K, Van Hoof ELS (2006). A Pediatric Case Definition for Myalgic Encephalomyelitis and Chronic Fatigue Syndrome. Journal of Chronic Fatigue Syndrome 13 (2-3): 1-44.
- ↑ 5.0 5.1 5.2 5.3 5.4 Carruthers BM, Jain AK, De Meirleir KL, Peterson DL, Klimas MD, Lerner AM, Bested AC, Flor-Henry P, Joshi P, Powles ACP, Sherkey JA, van de Sande MI (2003). Myalgic encephalomyalitis/chronic fatigue syndrome: Clinical working definition, diagnostic and treatment protocols. Journal of Chronic Fatigue Syndrome 11 (1): 7-36.
- ↑ 6.0 6.1 6.2 Jason LA, Taylor RR. (2001). Measuring Attributions About Chronic Fatigue Syndrome. J Chronic Fatigue Syndr 8 (3/4); 31-40 TXT formal
- ↑ Ranjith G (2005). Epidemiology of chronic fatigue syndrome.. Occup Med (Lond) 55 (1): 13-9. PMID 15699086.
- ↑ 8.0 8.1 Sharpe M, Archard L, Banatvala J, Borysiewicz L, Clare A, David A, Edwards R, Hawton K, Lambert H, Lane R (1991). A report--chronic fatigue syndrome: guidelines for research.. J R Soc Med 84 (2): 118-21. PMID 1999813. Synopsis by GPnotebook -476446699)
- ↑ 9.0 9.1 9.2 9.3 Fukuda K, Straus S, Hickie I, Sharpe M, Dobbins J, Komaroff A (1994). The chronic fatigue syndrome: a comprehensive approach to its definition and study. International Chronic Fatigue Syndrome Study Group.. Ann Intern Med 121 (12): 953-9. PMID 7978722. case definition
- ↑ 10.0 10.1 Afari N, Buchwald D (2003). Chronic fatigue syndrome: a review. Am J Psychiatr 160 (2): 221-36.
- ↑ 11.0 11.1 Chronic Fatigue Syndrome Basic Facts. (htm) Centers for Disease Control and Prevention. URL accessed on 2008-02-07.
- ↑ 12.0 12.1 [Anonymous] (1956). A new clinical entity?. Lancet 270 (6926): 789–90.
- ↑ Acheson E (1959). The clinical syndrome variously called benign myalgic encephalomyelitis, Iceland disease and epidemic neuromyasthenia.. Am J Med 26 (4): 569-95. PMID 13637100.
- ↑ (1962) Brain R Diseases of the Nervous System, 6.
- ↑ No authors listed. Epidemic myalgic encephalomyelitis. Br Med J. 1 (6125): 1436-7. PMID 647324.
- ↑ 16.0 16.1 16.2 Straus S, Tosato G, Armstrong G, Lawley T, Preble O, Henle W, Davey R, Pearson G, Epstein J, Brus I (1985). Persisting illness and fatigue in adults with evidence of Epstein-Barr virus infection.. Ann Intern Med 102 (1): 7-16. PMID 2578268.
- ↑ 17.0 17.1 17.2 Jones J, Ray C, Minnich L, Hicks M, Kibler R, Lucas D (1985). Evidence for active Epstein-Barr virus infection in patients with persistent, unexplained illnesses: elevated anti-early antigen antibodies.. Ann Intern Med 102 (1): 1-7. PMID 2578266.
- ↑ 18.0 18.1 18.2 Holmes G, Kaplan J, Gantz N, Komaroff A, Schonberger L, Straus S, Jones J, Dubois R, Cunningham-Rundles C, Pahwa S (1988). Chronic fatigue syndrome: a working case definition.. Ann Intern Med 108 (3): 387-9. PMID 2829679. Details
- ↑ Advocacy Archives: Name Change. The CFIDS Association of America. URL accessed on 2008-01-16.
- ↑ Lavrich, Carol (September 29 2003), Name Change Workgroup, CFSCC, National Institutes of Health Building 31C, Conference Room 10, Bethesda, Maryland: US Department of Health and Human Services, Chronic Fatigue Syndrome Advisory Committee, http://www.hhs.gov/advcomcfs/sept_meeting_min.html#carollavrich, retrieved on 2007-12-29
- ↑ Bell D.S. et al (December 03 2003), Name Change, Hubert H. Humphrey Building, 200 Independence Avenue, SW, Room 800, Washington, DC 20201: US Department of Health and Human Services Chronic Fatigue Syndrome Advisory Committee (CFSAC) Second Meeting, http://www.hhs.gov/advcomcfs/dec_meeting_min.html#name_change, retrieved on 2008-01-16
- ↑ 22.0 22.1 Buchwald D, Cheney P, Peterson D, Henry B, Wormsley S, Geiger A, Ablashi D, Salahuddin S, Saxinger C, Biddle R (1992). A chronic illness characterized by fatigue, neurologic and immunologic disorders, and active human herpesvirus type 6 infection.. Ann Intern Med 116 (2): 103-13. PMID 1309285.
- ↑ 23.0 23.1 Cho HJ, Skowera A, Cleare A, Wessely S (2006). Chronic fatigue syndrome: an update focusing on phenomenology and pathophysiology.. Curr Opin Psychiatry 19 (1): 67-73. PMID 16612182.
- ↑ 24.0 24.1 24.2 Ramsay MA (1986), "Postviral Fatigue Syndrome. The saga of Royal Free disease", Londen, ISBN 0-906923-96-4
- ↑ edited by Straus, Stephen E. (1994). Chronic Fatigue Syndrome, New York, Basel, Hong Kong: Marcel Dekker Inc..
- ↑ Aoki T, Usuda Y, Miyakoshi H, Tamura K, Herberman RB. (1987). Low natural killer syndrome: clinical and immunologic features. Nat Immun Cell Growth Regul. 6 (3): 116-28.
- ↑ Kitani T, Kuratsune H, Yamaguchi K. (Nov 1992). Diagnostic criteria for chronic fatigue syndrome by the CFS Study Group in Japan. Nippon Rinsho. 50 (11): 2600-5.
- ↑ Hashimoto N. et al (Jun 2007). History of chronic fatigue syndrome. Nippon Rinsho. 65 (6): 975-82.
- ↑ Cowley, Geoffrey, with Mary Hager and Nadine Joseph (1990-11-12), "Chronic Fatigue Syndrome", Newsweek: Cover Story
- ↑ Compact Oxford English Dictionary, Oxford University Press
- ↑ Packhard, Randall M. (2004). Emerging Illnesses and Society: Negotiating the Public Health Agenda. Johns Hopkins University Press, p. 156. ISBN 0-801-879-426
- ↑ Anon. "New Therapy For Chronic Fatigue Syndrome To Be Tested At Stanford" Medical News Today
- ↑ Blattner R (1956). Benign myalgic encephalomyelitis (Akureyri disease, Iceland disease). J. Pediatr. 49 (4): 504-6.
- ↑ 34.0 34.1 A. Melvin Ramsay (1986). Postviral Fatigue Syndrome. The saga of Royal Free disease.
- ↑ 35.0 35.1 Gilliam AG (1938) Epidemiological Study on an Epidemic, Diagnosed as Poliomyelitis, Occurring among the Personnel of Los Angeles County General Hospital during the Summer of 1934, United States Treasury Department Public Health Service Public Health Bulletin, No. 240, pp. 1-90. Washington, DC, Government Printing Office.
- ↑ 36.0 36.1 36.2 Salit IE (1997). Precipitating factors for the chronic fatigue syndrome.. J Psychiatr Res 31 (1): 59-65. PMID 9201648.
- ↑ Sairenji T, Nagata K (2007). Viral infections in chronic fatigue syndrome.. Nippon Rinsho 65 (6): 991-6. PMID 17561687.
- ↑ Evengård B, Jonzon E, Sandberg A, Theorell T, Lindh G (2003). Differences between patients with chronic fatigue syndrome and with chronic fatigue at an infectious disease clinic in Stockholm, Sweden.. Psychiatry Clin Neurosci 57 (4): 361-8. PMID 12839515.
- ↑ Evengård B, Schacterle RS, Komaroff AL (1999). Chronic fatigue syndrome: new insights and old ignorance.. J Intern Med 246 (5): 455-69. PMID 10583715.
- ↑ Jason LA, Taylor RR, Carrico AW (2001). A community-based study of seasonal variation in the onset of chronic fatigue syndrome and idiopathic chronic fatigue.. Chronobiol Int 18 (2): 315-9. PMID 11379670.
- ↑ Zhang QW, Natelson BH, Ottenweller JE, Servatius RJ, Nelson JJ, De Luca J, Tiersky L, Lange G (2000). Chronic fatigue syndrome beginning suddenly occurs seasonally over the year.. Chronobiol Int 17 (1): 95-9. PMID 10672437.
- ↑ Hatcher S, House A (2003). Life events, difficulties and dilemmas in the onset of chronic fatigue syndrome: a case-control study.. Psychol Med 33 (7): 1185-92. PMID 14580073.
- ↑ 43.0 43.1 Theorell T, Blomkvist V, Lindh G, Evengard B. Critical life events, infections, and symptoms during the year preceding chronic fatigue syndrome (CFS): an examination of CFS patients and subjects with a nonspecific life crisis.. Psychosom Med. 61 (3): 304-10. PMID 10367610.
- ↑ 44.0 44.1 Hickie I, Davenport T, Wakefield D, Vollmer-Conna U, Cameron B, Vernon SD, Reeves WC, Lloyd A; Dubbo Infection Outcomes Study Group (2006). Post-infective and chronic fatigue syndromes precipitated by viral and non-viral pathogens: prospective cohort study.. BMJ 333 (7568): 575. PMID 16950834.
- ↑ 45.0 45.1 De Becker P, McGregor N, De Meirleir K (2002). Possible Triggers and Mode of Onset of Chronic Fatigue Syndrome. Journal of Chronic Fatigue Syndrome 10 (2): 2-18.
- ↑ Donta S (2002). Late and chronic Lyme disease.. Med Clin North Am 86 (2): 341-9, vii. PMID 11982305.
- ↑ Krupp LB, Jandorf L, Coyle PK, Mendelson WB (1993). Sleep disturbance in chronic fatigue syndrome.. J Psychosom Res 37 (4): 325-31. PMID 8510058.
- ↑ Reeves WC, Heim C, Maloney EM, Youngblood LS, Unger ER, Decker MJ, Jones JF, Rye DB (2006). Sleep characteristics of persons with chronic fatigue syndrome and non-fatigued controls: results from a population-based study.. BMC Neurol 6: 41. PMID 17109739.
- ↑ Watson NF, Kapur V, Arguelles LM, Goldberg J, Schmidt DF, Armitage R, Buchwald D (2003). Comparison of subjective and objective measures of insomnia in monozygotic twins discordant for chronic fatigue syndrome.. Sleep 26 (3): 324-8. PMID 12749553.
- ↑ Van Hoof E, De Becker P, Lapp C, Cluydts R, De Meirleir K (2007). Defining the occurrence and influence of alpha-delta sleep in chronic fatigue syndrome.. Am J Med Sci 333 (2): 78-84. PMID 17301585.
- ↑ Ball N, Buchwald DS, Schmidt D, Goldberg J, Ashton S, Armitage R (2004). Monozygotic twins discordant for chronic fatigue syndrome: objective measures of sleep.. J Psychosom Res 56 (2): 207-12. PMID 15016580.
- ↑ 52.0 52.1 "Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: A Clinical Case Definition and Guidelines for Medical Practitioners - An Overview of the Canadian Consensus Document"; authored by Carruthers and van de Sande; published in 2005, ISBN 0-9739335-0-X, 
- ↑ 53.0 53.1 Meeus M, Nijs J, Meirleir KD (2007). Chronic musculoskeletal pain in patients with the chronic fatigue syndrome: A systematic review.. Eur J Pain 11 (4): 377-386. PMID 16843021.
- ↑ Michiels V, Cluydts R (2001). Neuropsychological functioning in chronic fatigue syndrome: a review.. Acta Psychiatr Scand 103 (2): 84-93. PMID 11167310.
- ↑ Burnet RB, Chatterton BE (2004). Gastric emptying is slow in chronic fatigue syndrome.. BMC Gastroenterol 4: 32. PMID 15619332.
- ↑ Woolley J, Allen R, Wessely S (2004). Alcohol use in chronic fatigue syndrome.. J Psychosom Res 56 (2): 203-6. PMID 15016579.
- ↑ McCully KK, Sisto SA, Natelson BH (1996). Use of exercise for treatment of chronic fatigue syndrome.. Sports Med 21 (1): 35-48. PMID 8771284.
- ↑ Solomon L, Nisenbaum R, Reyes M, Papanicolaou DA, Reeves WC (2003). Functional status of persons with chronic fatigue syndrome in the Wichita, Kansas, population.. Health Qual Life Outcomes 1 (1): 48. PMID 14577835.
- ↑  Press Conference: The Chronic Fatigue and Immune Dysfunction Syndrome Association of America and The Centers For Disease Control and Prevention Press Conference at The National Press Club to Launch a Chronic Fatigue Syndrome Awareness Campaign - November 3 2006, 10 a.m. ET
- ↑  The Centers For Disease Control and Prevention (website): Chronic Fatigue Syndrome > For Healthcare Professionals > Symptoms > Clinical Course
- ↑ Ho-Yen DO, McNamara I (1991). General practitioners' experience of the chronic fatigue syndrome. Br J Gen Pract 41 (349): 324-6. PMID 1777276.
- ↑ Vanness JM, Snell CR, Strayer DR, Dempsey L 4th, Stevens SR (2003). Subclassifying chronic fatigue syndrome through exercise testing.. Med Sci Sports Exerc 35 (6): 908-13. PMID 12783037.
- ↑ Ross SD, Estok RP, Frame D, Stone LR, Ludensky V, Levine CB (2004). Disability and chronic fatigue syndrome: a focus on function.. Arch Intern Med 164 (10): 1098-107. PMID 15159267.
- ↑ CDC - CFS Basic Overview (PDF file, 31 KB)
- ↑ Schwartz RB, Garada BM, Komaroff AL, et al (1994). Detection of intracranial abnormalities in patients with chronic fatigue syndrome: comparison of MR imaging and SPECT. AJR. American journal of roentgenology 162 (4): 935–41.
- ↑ Abu-Judeh HH, Levine S, Kumar M, et al (1998). Comparison of SPET brain perfusion and 18F-FDG brain metabolism in patients with chronic fatigue syndrome. Nuclear medicine communications 19 (11): 1065–71.
- ↑ Schwartz RB, Komaroff AL, Garada BM, et al (1994). SPECT imaging of the brain: comparison of findings in patients with chronic fatigue syndrome, AIDS dementia complex, and major unipolar depression. AJR. American journal of roentgenology 162 (4): 943–51.
- ↑ MacHale SM, Lawŕie SM, Cavanagh JT, et al (2000). Cerebral perfusion in chronic fatigue syndrome and depression. The British journal of psychiatry : the journal of mental science 176: 550–6.
- ↑ Fischler B, D'Haenen H, Cluydts R, et al (1996). Comparison of 99m Tc HMPAO SPECT scan between chronic fatigue syndrome, major depression and healthy controls: an exploratory study of clinical correlates of regional cerebral blood flow. Neuropsychobiology 34 (4): 175–83.
- ↑ Demitrack MA, Gold PW, Dale JK, Krahn DD, Kling MA, Straus SE (1992). Plasma and cerebrospinal fluid monoamine metabolism in patients with chronic fatigue syndrome: preliminary findings. Biol. Psychiatry 32 (12): 1065–77.
- ↑ Badawy AA, Morgan CJ, Llewelyn MB, Albuquerque SR, Farmer A (2005). Heterogeneity of serum tryptophan concentration and availability to the brain in patients with the chronic fatigue syndrome. J. Psychopharmacol. (Oxford) 19 (4): 385–91.
- ↑ Cleare AJ, Bearn J, Allain T, et al (1995). Contrasting neuroendocrine responses in depression and chronic fatigue syndrome. Journal of affective disorders 34 (4): 283–9.
- ↑ Cleare AJ, Messa C, Rabiner EA, Grasby PM (2005). Brain 5-HT1A receptor binding in chronic fatigue syndrome measured using positron emission tomography and [11C]WAY-100635. Biol. Psychiatry 57 (3): 239–46.
- ↑ Klein R, Berg PA (1995). High incidence of antibodies to 5-hydroxytryptamine, gangliosides and phospholipids in patients with chronic fatigue and fibromyalgia syndrome and their relatives: evidence for a clinical entity of both disorders. Eur. J. Med. Res. 1 (1): 21–6.
- ↑ Goertzel BN, Pennachin C, de Souza Coelho L, Gurbaxani B, Maloney EM, Jones JF (2006). Combinations of single nucleotide polymorphisms in neuroendocrine effector and receptor genes predict chronic fatigue syndrome. Pharmacogenomics 7 (3): 475–83.
- ↑ Dinan TG, Majeed T, Lavelle E, Scott LV, Berti C, Behan P (1997). Blunted serotonin-mediated activation of the hypothalamic-pituitary-adrenal axis in chronic fatigue syndrome. Psychoneuroendocrinology 22 (4): 261–7.
- ↑ 77.0 77.1 Kuratsune H, Yamaguti K, Lindh G, et al (2002). Brain regions involved in fatigue sensation: reduced acetylcarnitine uptake into the brain. Neuroimage 17 (3): 1256–65.
- ↑ Spence VA, Khan F, Kennedy G, Abbot NC, Belch JJ (2004). Acetylcholine mediated vasodilatation in the microcirculation of patients with chronic fatigue syndrome. Prostaglandins Leukot. Essent. Fatty Acids 70 (4): 403–7.
- ↑ Tanaka S, Kuratsune H, Hidaka Y, et al (2003). Autoantibodies against muscarinic cholinergic receptor in chronic fatigue syndrome. Int. J. Mol. Med. 12 (2): 225–30.
- ↑ Conti F, Pittoni V, Sacerdote P, Priori R, Meroni PL, Valesini G (1998). Decreased immunoreactive beta-endorphin in mononuclear leucocytes from patients with chronic fatigue syndrome. Clin. Exp. Rheumatol. 16 (6): 729–32.
- ↑ Panerai AE, Vecchiet J, Panzeri P, et al (2002). Peripheral blood mononuclear cell beta-endorphin concentration is decreased in chronic fatigue syndrome and fibromyalgia but not in depression: preliminary report. The Clinical journal of pain 18 (4): 270–3.
- ↑ Newton JL, Okonkwo O, Sutcliffe K, Seth A, Shin J, Jones DE (2007). Symptoms of autonomic dysfunction in chronic fatigue syndrome. QJM 100 (8): 519-26.
- ↑ 83.0 83.1 83.2 83.3 83.4 83.5 83.6 83.7 83.8 83.9 Byron M. Hyde (1992). The Clinical and scientific basis of myalgic encephalomyelitis/chronic fatigue syndrome, Ogdensburg, N.Y: Nightingale Research Foundation.
- ↑ Heller U, Becker EW, Zenner HP, Berg PA (1998). [Incidence and clinical relevance of antibodies to phospholipids, serotonin and ganglioside in patients with sudden deafness and progressive inner ear hearing loss]. HNO 46 (6): 583-6.
- ↑ Tolan R, Stewart J. "Chronic Fatigue Syndrome", eMedicine, August 17 2006, retrieved November 9 2006.
- ↑ Rowe, PC. "General Information Brochure on Orthostatic Intolerance and its Treatment", Chronic Fatigue Clinic, Johns Hopkins Children's Center, February 2003, retrieved November 9 2006.
- ↑ Rowe P, Calkins H, DeBusk K, McKenzie R, Anand R, Sharma G, Cuccherini B, Soto N, Hohman P, Snader S, Lucas K, Wolff M, Straus S (2001). Fludrocortisone acetate to treat neurally mediated hypotension in chronic fatigue syndrome: a randomized controlled trial. JAMA 285 (1): 52-9.
- ↑ 88.0 88.1 Stein E (2001), "How to differentiate CFS from Psychiatric Disorder", Presented at The Alison Hunter Memorial Foundation Third International Clinical and Scientific Conference, Sydney, Australia
- ↑ Heim C, Wagner D, Maloney E, Papanicolaou DA, Solomon L, Jones JF, Unger ER, Reeves WC (2006). Early adverse experience and risk for chronic fatigue syndrome: results from a population-based study.. Arch Gen Psychiatry 63 (11): 1258-66. PMID 17088506.
- ↑ Kato K, Sullivan PF, Evengard B, Pedersen NL (2006). Premorbid predictors of chronic fatigue.. Arch Gen Psychiatry 63 (11): 1267-72. PMID 17088507.
- ↑ T Chalder, R Goodman, S Wessely, M Hotopf, H Meltzer (2003). Epidemiology of chronic fatigue syndrome and self reported myalgic encephalomyelitis in 5-15 year olds: cross sectional study.. BMJ 327: 654-655. DOI 10.1136/bmj.327.7416.654.
- ↑ 92.0 92.1 92.2 Reeves W, Vernon S Press Briefing on Chronic Fatigue Syndrome. (HTM) Centers for Disease Control and Prevention. URL accessed on 2008-01-27.
- ↑ Roberts AD, Wessely S, Chalder T, Papadopoulos A, Cleare AJ (2004). Salivary cortisol response to awakening in chronic fatigue syndrome.. Br J Psychiatry 184: 136-41. PMID 14754825.
- ↑ Gaab J, Huster D, Peisen R, Engert V, Heitz V, Schad T, Schurmeyer TH, Ehlert U (2002). Hypothalamic-pituitary-adrenal axis reactivity in chronic fatigue syndrome and health under psychological, physiological, and pharmacological stimulation.. Psychosom Med 64 (6): 951-62. PMID 12461200.
- ↑ Gaab J, Engert V, Heitz V, Schad T, Schurmeyer TH, Ehlert U (2004). Associations between neuroendocrine responses to the Insulin Tolerance Test and patient characteristics in chronic fatigue syndrome.. J Psychosom Res 56 (4): 419-24. PMID 15094026.
- ↑ Kennedy G, Spence VA, McLaren M, Hill A, Underwood C, Belch JJ (2005). Oxidative stress levels are raised in CFS and are associated with clinical symptoms.. Free Radic Biol Med 39 (5): 584-9. PMID 16085177.
- ↑ Jammes Y, Steinberg JG, Mambrini O, Bregeon F, Delliaux S (2005). Chronic fatigue syndrome: assessment of increased oxidative stress and altered muscle excitability in response to incremental exercise.. J Intern Med 257 (3): 299-310. PMID 15715687.
- ↑ Richards RS, Wang L, Jelinek H (2007). Erythrocyte oxidative damage in chronic fatigue syndrome.. Arch Med Res 38 (1): 94-8. PMID 17174731.
- ↑ Vecchiet J, Cipollone F, Falasca K, Mezzetti A, Pizzigallo E, Bucciarelli T, De Laurentis S, Affaitati G, De Cesare D, Giamberardino MA (2003). Relationship between musculoskeletal symptoms and blood markers of oxidative stress in patients with chronic fatigue syndrome.. Neurosci Lett 335 (3): 151-4. PMID 12531455.
- ↑ Fulle S, Mecocci P, Fano G, Vecchiet I, Vecchini A, Racciotti D, Cherubini A, Pizzigallo E, Vecchiet L, Senin U, Beal MF (2000). Specific oxidative alterations in vastus lateralis muscle of patients with the diagnosis of chronic fatigue syndrome.. Free Radic Biol Med 29 (12): 1252-9. PMID 11118815.
- ↑ Richards RS, Roberts TK, McGregor NR, Dunstan RH, Butt HL (2000). Blood parameters indicative of oxidative stress are associated with symptom expression in chronic fatigue syndrome.. Redox Rep 5 (1): 35-41. PMID 10905542.
- ↑ Nijs J, Meeus M, De Meirleir K (2006). Chronic musculoskeletal pain in chronic fatigue syndrome: recent developments and therapeutic implications.. Man Ther 11 (3): 187-91. PMID 16781183.
- ↑ Maes M, Mihaylova I, Bosmans E (2007). Not in the mind of neurasthenic lazybones but in the cell nucleus: patients with chronic fatigue syndrome have increased production of nuclear factor kappa beta. Neuro Endocrinol. Lett. 28 (4): 456–62.
- ↑ 104.0 104.1 Snell CR, Vanness JM, Strayer DR, Stevens SR (2005). Exercise capacity and immune function in male and female patients with chronic fatigue syndrome (CFS).. In Vivo 19 (2): 387-90. PMID 15796202.
- ↑ Maes M, Mihaylova I, Leunis JC (2006). Chronic fatigue syndrome is accompanied by an IgM-related immune response directed against neopitopes formed by oxidative or nitrosative damage to lipids and proteins. Neuro Endocrinol. Lett. 27 (5): 615–21.
- ↑ Broderick G, Craddock RC, Whistler T, Taylor R, Klimas N, Unger ER (2006). Identifying illness parameters in fatiguing syndromes using classical projection methods. Pharmacogenomics 7 (3): 407–19.
- ↑ Siegel SD, Antoni MH, Fletcher MA, Maher K, Segota MC, Klimas N (2006). Impaired natural immunity, cognitive dysfunction, and physical symptoms in patients with chronic fatigue syndrome: preliminary evidence for a subgroup?. J Psychosom Res 60 (6): 559-66. PMID 16731230.
- ↑ Lyall M, Peakman M, Wessely S (2003). A systematic review and critical evaluation of the immunology of chronic fatigue syndrome.. J Psychosom Res 55 (2): 79-90. PMID 12932505.
- ↑ Tiev KP, Demettre E, Ercolano P, Bastide L, Lebleu B, Cabane J (2003). RNase L levels in peripheral blood mononuclear cells: 37-kilodalton/83-kilodalton isoform ratio is a potential test for chronic fatigue syndrome.. Clin Diagn Lab Immunol 10 (2): 315-6. PMID 12626460.
- ↑ Demettre E, Bastide L, D'Haese A, De Smet K, De Meirleir K, Tiev KP, Englebienne P, Lebleu B (2002). Ribonuclease L proteolysis in peripheral blood mononuclear cells of chronic fatigue syndrome patients.. J Biol Chem 277 (38): 35746-51. PMID 12118002.
- ↑ Shetzline SE, Martinand-Mari C, Reichenbach NL, Buletic Z, Lebleu B, Pfleiderer W, Charubala R, De Meirleir K, De Becker P, Peterson DL, Herst CV, Englebienne P, Suhadolnik RJ (2002). Structural and functional features of the 37-kDa 2-5A-dependent RNase L in chronic fatigue syndrome.. J Interferon Cytokine Res 22 (4): 443-56. PMID 12034027.
- ↑ 112.0 112.1 Suhadolnik RJ, Peterson DL, O'Brien K, Cheney PR, Herst CV, Reichenbach NL, Kon N, Horvath SE, Iacono KT, Adelson ME, De Meirleir K, De Becker P, Charubala R, Pfleiderer W (1997). Biochemical evidence for a novel low molecular weight 2-5A-dependent RNase L in chronic fatigue syndrome.. J Interferon Cytokine Res 17 (7): 377-85. PMID 9243369.
- ↑ Fremont M, El Bakkouri K, Vaeyens F, Herst CV, De Meirleir K, Englebienne P (2005). 2',5'-Oligoadenylate size is critical to protect RNase L against proteolytic cleavage in chronic fatigue syndrome.. Exp Mol Pathol 78 (3): 239-46. PMID 15924878.
- ↑ Suhadolnik RJ, Reichenbach NL, Hitzges P, Sobol RW, Peterson DL, Henry B, Ablashi DV, Muller WE, Schroder HC, Carter WA, et al (1994). Upregulation of the 2-5A synthetase/RNase L antiviral pathway associated with chronic fatigue syndrome.. Clin Infect Dis 18 (Suppl 1): S96-104. PMID 8148461.
- ↑ 115.0 115.1 Nijs J, De Meirleir K, Meeus M, McGregor NR, Englebienne P (2004). Chronic fatigue syndrome: intracellular immune deregulations as a possible etiology for abnormal exercise response.. Med Hypotheses 62 (5): 759-65. PMID 15082102.
- ↑ Snell CR, Vanness JM, Strayer DR, Stevens SR (2002). Physical performance and prediction of 2-5A synthetase/RNase L antiviral pathway activity in patients with chronic fatigue syndrome.. In Vivo 16 (2): 107-9. PMID 12073768.
- ↑ Nijs J, Meeus M, McGregor NR, Meeusen R, de Schutter G, van Hoof E, de Meirleir K (2005). Chronic fatigue syndrome: exercise performance related to immune dysfunction.. Med Sci Sports Exerc 37 (10): 1647-54. PMID 16260962.
- ↑ Nijs J, De Meirleir K (2005). Impairments of the 2-5A synthetase/RNase L pathway in chronic fatigue syndrome.. In Vivo 19 (6): 1013-21. PMID 16277015.
- ↑ Van Hoof E, De Becker P, Lapp C, Cluydts R, De Meirleir K (2007). Defining the occurrence and influence of alpha-delta sleep in chronic fatigue syndrome.. Am J Med Sci 333 (2): 78-84. PMID 17301585.
- ↑ Kennedy G, Spence V, Underwood C, Belch JJ. Increased neutrophil apoptosis in chronic fatigue syndrome. J Clin Pathol. 2004 Aug;57(8):891-3.
- ↑ Patarca R, Klimas NG, Lugtendorf S, Antoni M, Fletcher MA. Dysregulated expression of tumor necrosis factor in chronic fatigue syndrome: interrelations with cellular sources and patterns of soluble immune mediator expression. Clin Infect Dis. 1994 Jan;18 Suppl 1:S147-53.
- ↑ Original Research Paper, from the Journal of Clinical Pathology http://www.cfids.org/cfidslink/2005/cfs-gene.pdf
- ↑ (Jan. 2001) "Food Intolerance in Chronic Fatigue Syndrome". ': Conference Paper 15, Seattle WA: American Association for Chronic Fatigue Syndrome.
- ↑ 124.0 124.1 124.2 Logan AC, Wong C (2001). Chronic fatigue syndrome: oxidative stress and dietary modifications. Alternative medicine review : a journal of clinical therapeutic 6 (5): 450-9.
- ↑ Lloyd A, Wakefield D, Boughton C, Dwyer J (1989). Immunological abnormalities in the chronic fatigue syndrome.. Med J Aust 151 (3): 122-4. PMID 2787888.
- ↑ Bennett AL, Chao CC, Hu S, Buchwald D, Fagioli LR, Schur PH, Peterson PK, Komaroff AL (1997). Elevation of bioactive transforming growth factor-beta in serum from patients with chronic fatigue syndrome.. J Clin Immunol 17 (2): 160-6. PMID 9083892.
- ↑ Natelson BH, Ellis SP, Braonain PJ, DeLuca J, Tapp WN (1995). Frequency of deviant immunological test values in chronic fatigue syndrome patients.. Clin Diagn Lab Immunol 2 (2): 238-40. PMID 7697537.
- ↑ Maes M, Mihaylova I, Leunis JC (2006). Chronic fatigue syndrome is accompanied by an IgM-related immune response directed against neopitopes formed by oxidative or nitrosative damage to lipids and proteins.. Neuro Endocrinol Lett 27 (5): 615-21. PMID 17159817.
- ↑ Sorensen B, Streib JE, Strand M, Make B, Giclas PC, Fleshner M, Jones JF (2003). Complement activation in a model of chronic fatigue syndrome.. J Allergy Clin Immunol 112 (2): 397-403. PMID 12897748.
- ↑ Margutti P, Delunardo F, Ortona E (2006). Autoantibodies associated with psychiatric disorders.. Curr Neurovasc Res 3 (2): 149-57. PMID 16719797.
- ↑ Vollmer-Conna U, Lloyd A, Hickie I, Wakefield D (1998). Chronic fatigue syndrome: an immunological perspective.. Aust N Z J Psychiatry 32 (4): 523-7. PMID 9711366.
- ↑ Tanaka S, Kuratsune H, Hidaka Y, Hakariya Y, Tatsumi KI, Takano T, Kanakura Y, Amino N (2003). Autoantibodies against muscarinic cholinergic receptor in chronic fatigue syndrome.. Int J Mol Med 12 (2): 225-30. PMID 12851722.
- ↑ Nijs J, Van de Velde B, De Meirleir K (2005). Pain in patients with chronic fatigue syndrome: does nitric oxide trigger central sensitisation?. Med Hypotheses 64 (3): 558-62. PMID 15617866.
- ↑ Chia JK, Chia AY (2007). Chronic fatigue syndrome is associated with chronic enterovirus infection of the stomach. J Clin Pathol Online preprint.
- ↑ Holmes GP, Kaplan JE, Stewart JA, Hunt B, Pinsky PF, Schonberger LB (1987). A cluster of patients with a chronic mononucleosis-like syndrome. Is Epstein-Barr virus the cause?. JAMA 257 (17): 2297-302.
- ↑ Kawai K, Kawai A (1992). Studies on the relationship between chronic fatigue syndrome and Epstein-Barr virus in Japan.. Intern Med 31 (3): 313-8. PMID 1319246.
- ↑ Lerner A, Beqaj S, Deeter R, Fitzgerald J (2004). IgM serum antibodies to Epstein-Barr virus are uniquely present in a subset of patients with the chronic fatigue syndrome.. In Vivo 18 (2): 101-6. PMID 15113035.
- ↑ Ablashi D, Eastman H, Owen C, Roman M, Friedman J, Zabriskie J, Peterson D, Pearson G, Whitman J (2000). Frequent HHV-6 reactivation in multiple sclerosis (MS) and chronic fatigue syndrome (CFS) patients.. J Clin Virol 16 (3): 179-91. PMID 10738137.
- ↑ De Bolle L, Naesens L, De Clercq E (2005). Update on human herpesvirus 6 biology, clinical features, and therapy.. Clin Microbiol Rev 18 (1): 217-45. PMID 15653828.
- ↑ Krueger G, Koch B, Hoffmann A, Rojo J, Brandt M, Wang G, Buja L. Dynamics of chronic active herpesvirus-6 infection in patients with chronic fatigue syndrome: data acquisition for computer modeling.. In Vivo 15 (6): 461-5. PMID 11887330.
- ↑ Caserta M, Mock D, Dewhurst S (2001). Human herpesvirus 6.. Clin Infect Dis 33 (6): 829-33. PMID 11512088.
- ↑ Yalcin S, Kuratsune H, Yamaguchi K, Kitani T, Yamanishi K (1994). Prevalence of human herpesvirus 6 variants A and B in patients with chronic fatigue syndrome.. Microbiol Immunol 38 (7): 587-90. PMID 7968694.
- ↑ Sairenji T, Yamanishi K, Tachibana Y, Bertoni G, Kurata T (1995). Antibody responses to Epstein-Barr virus, human herpesvirus 6 and human herpesvirus 7 in patients with chronic fatigue syndrome.. Intervirology 38 (5): 269-73. PMID 8724857.
- ↑ Patnaik M, Komaroff A, Conley E, Ojo-Amaize E, Peter J (1995). Prevalence of IgM antibodies to human herpesvirus 6 early antigen (p41/38) in patients with chronic fatigue syndrome.. J Infect Dis 172 (5): 1364-7. PMID 7594679.
- ↑ Komaroff AL. (2006 Dec). Is human herpesvirus-6 a trigger for chronic fatigue syndrome. J Clin Virol. 37 (Suppl 1): S39-46.
- ↑ (2000) Chronic Fatigue Syndrome and Herpesviruses: the Fading Evidence.. Herpes 7 (2): 46-50. PMID 11867001.
- ↑ Demitrack MA, Dale JK, Straus SE, et al (1991). Evidence for impaired activation of the hypothalamic-pituitary-adrenal axis in patients with chronic fatigue syndrome. J. Clin. Endocrinol. Metab. 73 (6): 1224–34.
- ↑ Cleare AJ (2003). The neuroendocrinology of chronic fatigue syndrome. Endocr. Rev. 24 (2): 236–52.
- ↑ 149.0 149.1 Van Den Eede F, Moorkens G, Van Houdenhove B, Cosyns P, Claes SJ (2007). Hypothalamic-pituitary-adrenal axis function in chronic fatigue syndrome. Neuropsychobiology 55 (2): 112–20.
- ↑  The Centers For Disease Control and Prevention (website): CFS Home > Publications > Molecular Epidemiology Program - Date: July 25 2005 - Content source: National Center for Infectious Diseases
- ↑ Whistler T, Jones JF, Unger ER, Vernon SD (2005). Exercise responsive genes measured in peripheral blood of women with chronic fatigue syndrome and matched control subjects.. BMC Physiol 5 (1): 5. PMID 15790422.
- ↑ Whistler T, Unger ER, Nisenbaum R, Vernon SD (2003). Integration of gene expression, clinical, and epidemiologic data to characterize Chronic Fatigue Syndrome.. J Transl Med 1 (1): 10. PMID 14641939.
- ↑ Vernon SD, Unger ER, Dimulescu IM, Rajeevan M, Reeves WC (2002). Utility of the blood for gene expression profiling and biomarker discovery in chronic fatigue syndrome.. Dis Markers 18 (4): 193-9. PMID 12590173.
- ↑ Kaushik N, Fear D, Richards SC, McDermott CR, Nuwaysir EF, Kellam P, Harrison TJ, Wilkinson RJ, Tyrrell DA, Holgate ST, Kerr JR (2005). Gene expression in peripheral blood mononuclear cells from patients with chronic fatigue syndrome.. J Clin Pathol 58 (8): 826-32. PMID 16049284.
- ↑ Fang H, Xie Q, Boneva R, Fostel J, Perkins R, Tong W (2006). Gene expression profile exploration of a large dataset on chronic fatigue syndrome.. Pharmacogenomics 7 (3): 429-40. PMID 16610953.
- ↑ BBC News (28 May 2005) - Scientists 'unlock ME genetics' (study still in its early stages)
- ↑ Fostel J, Boneva R, Lloyd A (2006). Exploration of the gene expression correlates of chronic unexplained fatigue using factor analysis.. Pharmacogenomics 7 (3): 441-54. PMID 16610954.
- ↑ Kerr J, Burke B, Petty R, et al (2007). Seven genomic subtypes of Chronic Fatigue Syndrome / Myalgic Encephalomyelitis (CFS/ME): a detailed analysis of gene networks and clinical phenotypes. J Clin Pathol.
- ↑ Smith AK, Dimulescu I, Falkenberg VR, et al (2008). Genetic evaluation of the serotonergic system in chronic fatigue syndrome. Psychoneuroendocrinology 33 (2): 188–97.
- ↑ Narita M, Nishigami N, Narita N, Yamaguti K, Okado N, Watanabe Y, Kuratsune H (2003). Association between serotonin transporter gene polymorphism and chronic fatigue syndrome. Biochem. Biophys. Res. Commun. 311 (2): 264-6.
- ↑ Goertzel BN, Pennachin C, de Souza Coelho L, Gurbaxani B, Maloney EM, Jones JF (2006). Combinations of single nucleotide polymorphisms in neuroendocrine effector and receptor genes predict chronic fatigue syndrome. Pharmacogenomics 7 (3): 475-83.
- ↑ Smith AK, White PD, Aslakson E, Vollmer-Conna U, Rajeevan MS (2006). Polymorphisms in genes regulating the HPA axis associated with empirically delineated classes of unexplained chronic fatigue. Pharmacogenomics 7 (3): 387-94.
- ↑ Torpy DJ, Bachmann AW, Gartside M, Grice JE, Harris JM, Clifton P, Easteal S, Jackson RV, Whitworth JA (2004). Association between chronic fatigue syndrome and the corticosteroid-binding globulin gene ALA SER224 polymorphism. Endocr. Res. 30 (3): 417-29.
- ↑ Kerr JR (2005). Pathogenesis of parvovirus B19 infection: host gene variability, and possible means and effects of virus persistence. J. Vet. Med. B Infect. Dis. Vet. Public Health 52 (7-8): 335-9.
- ↑ Carlo-Stella N, Badulli C, De Silvestri A, Bazzichi L, Martinetti M, Lorusso L, Bombardieri S, Salvaneschi L, Cuccia M (2006). A first study of cytokine genomic polymorphisms in CFS: Positive association of TNF-857 and IFNgamma 874 rare alleles. Clin. Exp. Rheumatol. 24 (2): 179-82.
- ↑ Vladutiu GD, Natelson BH (2004). Association of medically unexplained fatigue with ACE insertion/deletion polymorphism in Gulf War veterans. Muscle Nerve 30 (1): 38-43.
- ↑ Wyller VB (2007). The chronic fatigue syndrome - an update. Acta Neurol Scand Suppl 187: 7-14. PMID 17419822.
- ↑ Behan WM, More IA, Behan PO (1991), "Mitochondrial abnormalities in the postviral fatigue syndrome", Acta Neuropathol. 1991;83(1):61-5, PMID: 1792865
- ↑ Lundell K, Qazi S, Eddy L, Uckun FM. Clinical activity of folinic acid in patients with chronic fatigue syndrome. Arzneimittelforschung. 2006;56(6):399-404.
- ↑ Jacobson W, Saich T, Borysiewicz LK, Behan WM, Behan PO, Wreghitt TG. Serum folate and chronic fatigue syndrome. Neurology 1993 Dec;43(12):2645-7.
- ↑ Fernández-Solà J, Lluís Padierna M, Nogué Xarau S, Munné Mas P (2005). [Chronic fatigue syndrome and multiple chemical hypersensitivity after insecticide exposure]. Med Clin (Barc) 124 (12): 451–3.
- ↑ Dunstan RH, Donohoe M, Taylor W, et al (1995). A preliminary investigation of chlorinated hydrocarbons and chronic fatigue syndrome. Med. J. Aust. 163 (6): 294–7.
- ↑ Viner R, Hotopf M (2003). Childhood predictors of self reported chronic fatigue syndrome/myalgic encephalomyelitis in adults: national birth cohort study.. BMJ 329 (7472): 941. PMID 15469945.
- ↑ Lane RJ, Soteriou BA, Zhang H, Archard LC (2003). Enterovirus related metabolic myopathy: a postviral fatigue syndrome.. J Neurol Neurosurg Psychiatry 74 (10): 1382-6. PMID 14570830.
- ↑ Cameron B, Bharadwaj M, Burrows J, Fazou C, Wakefield D, Hickie I, Ffrench R, Khanna R, Lloyd A (2006). Prolonged illness after infectious mononucleosis is associated with altered immunity but not with increased viral load.. J Infect Dis 193 (5): 664-71. PMID 16453261.
- ↑ Lane RJ, Barrett MC, Taylor DJ, Kemp GJ, Lodi R (1998). Heterogeneity in chronic fatigue syndrome: evidence from magnetic resonance spectroscopy of muscle. Neuromuscul. Disord. 8 (3-4): 204–9.
- ↑ Lane RJ, Barrett MC, Woodrow D, Moss J, Fletcher R, Archard LC (1998). Muscle fibre characteristics and lactate responses to exercise in chronic fatigue syndrome. J. Neurol. Neurosurg. Psychiatr. 64 (3): 362–7.
- ↑ Lane RJ, Soteriou BA, Zhang H, Archard LC (2003). Enterovirus related metabolic myopathy: a postviral fatigue syndrome. J. Neurol. Neurosurg. Psychiatr. 74 (10): 1382–6.
- ↑ Lamb GD, Stephenson DG (2006). Point: lactic acid accumulation is an advantage during muscle activity. J. Appl. Physiol. 100 (4): 1410–2; discussion 1414.
- ↑ Pedersen TH, Nielsen OB, Lamb GD, Stephenson DG (2004). Intracellular acidosis enhances the excitability of working muscle.. Science 305 (5687): 1144-7. PMID 15326352.
- ↑ Horrobin, David F. (1990). Omega-6 essential fatty acids: pathophysiology and roles in clinical medicine, 275-282, New York: Wiley-Liss.
- ↑ 182.0 182.1 Behan PO, Behan WM, Horrobin D (1990). Effect of high doses of essential fatty acids on the postviral fatigue syndrome. Acta Neurol. Scand. 82 (3): 209-16.
- ↑ Ogawa R, Toyama S, Matsumoto H. (1992). Chronic fatigue syndrome--cases in the Kanebo Memorial Hospital. Nippon Rinsho. 50 (11): 2648-52.
- ↑ Liu Z, Wang D, Xue Q, et al (2003). Determination of fatty acid levels in erythrocyte membranes of patients with chronic fatigue syndrome. Nutritional neuroscience 6 (6): 389-92.
- ↑ Maes M, Mihaylova I, Leunis JC (2005). In chronic fatigue syndrome, the decreased levels of omega-3 poly-unsaturated fatty acids are related to lowered serum zinc and defects in T cell activation. Neuro Endocrinol. Lett. 26 (6): 745–51.
- ↑ 186.0 186.1 Warren G, McKendrick M, Peet M (1999). The role of essential fatty acids in chronic fatigue syndrome. A case-controlled study of red-cell membrane essential fatty acids (EFA) and a placebo-controlled treatment study with high dose of EFA. Acta Neurol. Scand. 99 (2): 112-6.
- ↑ 187.0 187.1 Puri BK (2007). Long-chain polyunsaturated fatty acids and the pathophysiology of myalgic encephalomyelitis (chronic fatigue syndrome). J. Clin. Pathol. 60 (2): 122–4.
- ↑ 188.0 188.1 Puri BK (2004). The use of eicosapentaenoic acid in the treatment of chronic fatigue syndrome. Prostaglandins Leukot. Essent. Fatty Acids 70 (4): 399–401.
- ↑ Carruthers, BM, Jain AK et. al. (2003). Myalgic Encephomyelitis / Chronic fatigue Syndrome: Clinical Working Case Definition, Diagnostic and Treatment Protocols (a Consensus Document). Journal of Chronic Fatigue Syndrome 11 (1): 66.
- ↑ Jenkins, Rachel; Mowbray, James F. (1991). Post-viral fatigue syndrome (Myalgic encephalomyelitis), New York: Wiley.
- ↑ 191.0 191.1 Kuratsune H, Yamaguti K, Takahashi M, Misaki H, Tagawa S, Kitani T (1994). Acylcarnitine deficiency in chronic fatigue syndrome. Clin. Infect. Dis. 18 Suppl 1: S62–7.
- ↑ Plioplys AV, Plioplys S (1995). Serum levels of carnitine in chronic fatigue syndrome: clinical correlates. Neuropsychobiology 32 (3): 132–8.
- ↑ Kuratsune H, Yamaguti K, Lindh G, et al (1998). Low levels of serum acylcarnitine in chronic fatigue syndrome and chronic hepatitis type C, but not seen in other diseases. Int. J. Mol. Med. 2 (1): 51–6.
- ↑ Miwa S, Takikawa O (2007). [Chronic fatigue syndrome and neurotransmitters]. Nippon Rinsho 65 (6): 1005–10.
- ↑ Jones MG, Goodwin CS, Amjad S, Chalmers RA (2005). Plasma and urinary carnitine and acylcarnitines in chronic fatigue syndrome. Clin. Chim. Acta 360 (1-2): 173–7.
- ↑ Li YJ, Wang DX, Bai XL, et al (2005). [Clinical characteristics of patients with chronic fatigue syndrome: analysis of 82 cases]. Zhonghua Yi Xue Za Zhi 85 (10): 701–4.
- ↑ Barron DF, Cohen BA, Geraghty MT, Violand R, Rowe PC (2002). Joint hypermobility is more common in children with chronic fatigue syndrome than in healthy controls.. J Pediatr 141 (3): 421-5. PMID 12219066.
- ↑ 198.0 198.1 198.2 198.3 198.4 National Institute for Health and Clinical Excellence. Guideline 53: Chronic fatigue syndrome/myalgic encephalomyelitis (or encephalopathy). London, 2007. ISBN 1846294533. NICE CG53 page.
- ↑ The ME Association - NICE guideline on ME/CFS - MEA statement. URL accessed on 2007-10-09.
- ↑ Australian Guidelines (2004)
- ↑ Jason LA, Corradi K, Torres-Harding S, Taylor RR, King C (2005). Chronic fatigue syndrome: the need for subtypes.. Neuropsychol Rev 15 (1): 29-58. PMID 15929497.
- ↑ Reeves WC, Lloyd A, Vernon SD, Klimas N, Jason LA, Bleijenberg G, Evengard B, White PD, Nisenbaum R, Unger ER (2003). Identification of ambiguities in the 1994 chronic fatigue syndrome research case definition and recommendations for resolution.. BMC Health Serv Res 3 (1): 25. PMID 14702202.
- ↑ Kennedy G, Abbot NC, Spence V, Underwood C, Belch JJ (2004). The specificity of the CDC-1994 criteria for chronic fatigue syndrome: comparison of health status in three groups of patients who fulfill the criteria.. Ann Epidemiol 14 (2): 95-100. PMID 15018881.
- ↑ Jason LA, Helgerson J, Torres-Harding SR, Carrico AW, Taylor RR (2003). Variability in diagnostic criteria for chronic fatigue syndrome may result in substantial differences in patterns of symptoms and disability.. Eval Health Prof 26 (1): 3-22. PMID 12629919.
- ↑ King C, Jason LA (2005). Improving the diagnostic criteria and procedures for chronic fatigue syndrome.. Biol Psychol 68 (2): 87-106. PMID 15450690.
- ↑ Hawk C, Jason LA, Torres-Harding S (2006). Differential diagnosis of chronic fatigue syndrome and major depressive disorder.. Int J Behav Med 13 (3): 244-51. PMID 17078775.
- ↑ Komaroff AL, Fagioli LR, Geiger AM, Doolittle TH, Lee J, Kornish RJ, Gleit MA, Guerriero RT (1996). An examination of the working case definition of chronic fatigue syndrome.. Am J Med 100 (1): 56-64. PMID 8579088.
- ↑ Jason LA, Torres-Harding SR, Jurgens A, Helgerson J (2004). Comparing the Fukuda et al. Criteria and the Canadian Case Definition for Chronic Fatigue Syndrome.. Journal of Chronic Fatigue Syndrome 12 (1): 37 - 52.
- ↑ Jason LA, Taylor RR, Kennedy CL, Jordan KM, Song S, Johnson D, Torres-Harding S (2003). Chronic fatigue syndrome: symptom subtypes in a community based sample.. Women Health 37 (1): 1-13. PMID 12627607.
- ↑ Jason LA, Taylor RR, Kennedy CL, Song S, Johnson D, Torres S (2000). Chronic fatigue syndrome: occupation, medical utilization, and subtypes in a community-based sample.. J Nerv Ment Dis 188 (9): 568-76. PMID 11009329.
- ↑ Janal MN, Ciccone DS, Natelson BH (2006). Sub-typing CFS patients on the basis of 'minor' symptoms.. Biol Psychol 73 (2): 124-31. PMID 16473456.
- ↑ Maoz D, Shoenfeld Y (2006). Chronic fatigue syndrome. Harefuah 145 (4): 272-5, 319, 318. PMID 16642629.
- ↑ Torres-Harding SR, Jason LA, Cane V, Carrico A, Taylor RR (2002). Physicians' diagnoses of psychiatric disorders for people with chronic fatigue syndrome.. Int J Psychiatry Med 32 (2): 109-24. PMID 12269593.
- ↑ Ryan TA (1944). Varieties of Fatigue. Am J Psychol 57;565-569.
- REDIRECT Template:Doi
- ↑ Jason LA, Taylor RR, Plioplys S, Stepanek Z, Shlaes J (2002). Evaluating attributions for an illness based upon the name: chronic fatigue syndrome, myalgic encephalopathy and Florence Nightingale disease.. Am J Community Psychol 30 (1): 133-48. PMID 11928774.
- ↑ Jason LA, Holbert C, Torres-Harding S, Taylor RR, LeVasseur JJ, Breitinger P, LaBarbera D, Siegel L (2003). Chronic fatigue syndrome versus neuroendocrineimmune dysfunction syndrome:differential attributions.. J Health Soc Policy 18 (1): 43-55. PMID 15189800.
- ↑ Hyde B. (2007), "The Nightingale Myalgic Encephalomyelitis (M.E.) Definition", The Nightingale Research Foundation, Ottawa, Canada
- ↑ Jason LA, Richman JA, Friedberg F, Wagner L, Taylor R, Jordan KM (1997). Politics, science, and the emergence of a new disease. The case of chronic fatigue syndrome.. Am Psychol 52 (9): 973-83. PMID 9301342.
- ↑ 219.0 219.1 CFS/ME Working Group. A report of the CFS/ME working group: report to the chief medical officer of an independent working group. London: Department of Health, 2002. Fulltext at DOH.
- ↑ 220.0 220.1 June 7 2006 . Dr. Gerberding's address at CFS awareness campaign launch Department of Health and Human Services. Centers for Disease Control and Prevention.
- ↑ Centers for Disease Control and Prevention (2006), " CFS Toolkit: Fact Sheets for Healthcare Professionals"
- ↑ 222.0 222.1 222.2 222.3 Report of the Group on Scientific Research into Myalgic Encephalomyelitis 2006
- ↑ 223.0 223.1 223.2 Hooper M (2006). Myalgic Encephalomyelitis (ME): a review with emphasis on key findings in biomedical research.. J Clin Pathol.
- ↑ Van Houdenhove B (2006). What is the aim of cognitive behaviour therapy in patients with chronic fatigue syndrome?. Journal of Psychotherapy and Psychosomatics 75 (6): 396-7. PMID 17053343.
- ↑ Rimes KA, Chalder T. (2005). Treatments for chronic fatigue syndrome.. Occupational Medicine 55 (1): 32-39. PMID 15699088.
- ↑ Cho HJ, Hotopf M, Wessely S (2005). The placebo response in the treatment of chronic fatigue syndrome: a systematic review and meta-analysis.. Psychosom Med 67 (2): 301-13. PMID 15784798.
- ↑ 227.0 227.1 [Chambers D, Bagnall AM, Hempel S, Forbes C (2006). Interventions for the treatment, management and rehabilitation of patients with chronic fatigue syndrome/myalgic encephalomyelitis: an updated systematic review. Journal of the Royal Society of Medicine 99 (10): 506-20.
- ↑ Ross SD, Levine C, Ganz N, Frame D, Estok R, Stone L, Ludensky V (2002). Systematic review of the current literature related to disability and chronic fatigue syndrome.. Evid Rep Technol Assess (Summ) (66): 1-3. PMID 12647509.
- ↑ Ross SD, Estok RP, Frame D, Stone LR, Ludensky V, Levine CB (2004). Disability and chronic fatigue syndrome: a focus on function. Arch. Intern. Med. 164 (10): 1098-107.
- ↑  Action for ME's "Review of Gibson Inquiry Report" (27 November 2006)
- ↑  The ME Association's "Gibson Report: key points raised by The ME Association" (6 February 2007)
- ↑  The One Click Group's "The One Click Group Report - The Gibson 'Inquiry'" (17 January 2007)
- ↑ 
- ↑ Peter D White, Michael C Sharpe, Trudie Chalder, Julia C DeCesare, Rebecca Walwyn for the PACE trial group (2007). Protocol for the PACE trial: A randomised controlled trial of adaptive pacing, cognitive behaviour therapy, and graded exercise as supplements to standardised specialist medical care versus standardised specialist medical care alone for patients with the chronic fatigue syndrome/myalgic encephalomyelitis or encephalopathy.. BMC Neurology 7:6. DOI 10.1186/1471-2377-7-6.
- ↑ 
- ↑ Youssefi M, Linkowski P (2002). Chronic fatigue syndrome: psychiatric perspectives. Rev Med Brux 23 (4): A299-304. PMID 12422451.
- ↑ Patel MX, Smith DG, Chalder T, Wessely S (2003). Chronic fatigue syndrome in children: a cross sectional survey. Arch Dis Child 88 (10): 894-8. PMID 14500310.
- ↑  www.me-cfs-treatment.com
- ↑  www.mind.org.uk
- ↑ Deale A, Husain K, Chalder T, Wessely S (2001). Long-term outcome of cognitive behavior therapy versus relaxation therapy for chronic fatigue syndrome: a 5-year follow-up study.. Am J Psychiatry 158 (12): 2038-42. PMID 11729022.
- ↑ RIZIV, "Referentiecentra voor het Chronisch vermoeidheidssyndroom (CVS), evaluatierapport 2002-2004", Brussels, July 2006
- ↑ Knoop H, Prins JB, Stulemeijer M, van der Meer JW, Bleijenberg G (2007). The effect of cognitive behaviour therapy for chronic fatigue syndrome on self-reported cognitive impairments and neuropsychological test performance.. J Neurol Neurosurg Psychiatry 78 (4): 434-6. PMID 17369597.
- ↑ Knoop H, Stulemeijer M, Prins JB, van der Meer JW, Bleijenberg G. Is cognitive behaviour therapy for chronic fatigue syndrome also effective for pain symptoms?. Behav Res Ther (March 14 2007). PMID 17451642.
- ↑ Ridsdale L, Godfrey E, Chalder T, Seed P, King M, Wallace P, Wessely S (2001). Chronic fatigue in general practice: is counselling as good as cognitive behaviour therapy? A UK randomised trial.. Br J Gen Pract 51 (462): 19-24. PMID 11271868.
- ↑ Moss-Morris R, Sharon C, Tobin R, Baldi JC (2005). A randomized controlled graded exercise trial for chronic fatigue syndrome: outcomes and mechanisms of change.. J Health Psychol 10 (2): 245-59. PMID 15723894.
- ↑ [Bell David S] (1994). The Doctor's Guide to Chronic Fatigue Syndrome, 163, Da Capo Press.
- ↑ Thomas MA, Smith AP.An investigation of the long-term benefits of antidepressant medication in the recovery of patients with chronic fatigue syndrome. Hum Psychopharmacol. 2006 Dec;21(8):503-9
- ↑ Schonfeldt-Lecuona C, Connemann BJ, Wolf RC, Braun M, Freudenmann RW.Bupropion augmentation in the treatment of chronic fatigue syndrome with coexistent major depression episode. Pharmacopsychiatry. 2006 Jul;39(4):152-4.
- ↑ Goodnick PJ, Sandoval R, Brickman A, Klimas NG.Bupropion treatment of fluoxetine-resistant chronic fatigue syndrome. Biol Psychiatry. 1992 Nov 1;32(9):834-8.
- ↑ Hickie IB, Wilson AJ, Wright JM, Bennett BK, Wakefield D, Lloyd AR. A randomized, double-blind placebo-controlled trial of moclobemide in patients with chronic fatigue syndrome. J Clin Psychiatry. 2000 Sep;61(9):643-8.
- ↑ Blockmans D, Persoons P, Van Houdenhove B, Bobbaers H (2006). Does methylphenidate reduce the symptoms of chronic fatigue syndrome?. Am J Med 119 (2): 167.e23-30. PMID 16443425.
- ↑ Randall DC, Cafferty FH, Shneerson JM, Smith IE, Llewelyn MB, File SE (2005). Chronic treatment with modafinil may not be beneficial in patients with chronic fatigue syndrome.. J Psychopharmacol 19 (6): 647-60. PMID 16272188.
- ↑ Teitelbaum J, Bird B, Weiss A, Gould L (1999). Low-dose hydrocortisone for chronic fatigue syndrome.. JAMA 281 (20): 1887-8; author reply 1888-9. PMID 10349885.
- ↑ Naranch K, Park YJ, Repka-Ramirez MS, Velarde A, Clauw D, Baraniuk JN (2002). A tender sinus does not always mean rhinosinusitis. Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery 127 (5): 387-97.
- ↑ Baraniuk JN, Clauw DJ, Gaumond E (1998). Rhinitis symptoms in chronic fatigue syndrome. Ann. Allergy Asthma Immunol. 81 (4): 359-65.
- ↑ Moss-Morris R, Spence M (2006). To "lump" or to "split" the functional somatic syndromes: can infectious and emotional risk factors differentiate between the onset of chronic fatigue syndrome and irritable bowel syndrome?. Psychosomatic medicine 68 (3): 463-9.
- ↑ Aaron LA, Burke MM, Buchwald D (2000). Overlapping conditions among patients with chronic fatigue syndrome, fibromyalgia, and temporomandibular disorder. Arch. Intern. Med. 160 (2): 221-7.
- ↑ 258.0 258.1 Reid S, Chadler T, Cleare A, Hotopf M, Wessely S. (2000). Extracts from “Clinical Evidence”: Chronic fatigue syndrome. British Medical Journal 320 (7230): 292–296.
- ↑ Cox IM, Campbell MJ, Dowson D (1991). Red blood cell magnesium and chronic fatigue syndrome. Lancet 337 (8744): 757-60.
- ↑ Jones JF, Maloney EM, Boneva RS, Jones AB, Reeves WC (2007). Complementary and alternative medical therapy utilization by people with chronic fatiguing illnesses in the United States. BMC Complement Altern Med 7: 12.
- ↑ Afari N, Eisenberg DM, Herrell R, et al (2000). Use of alternative treatments by chronic fatigue syndrome discordant twins. Integr Med 2 (2): 97–103.
- ↑ 262.0 262.1 Cairns R, Hotopf M (2005). A systematic review describing the prognosis of chronic fatigue syndrome. Occupational medicine (Oxford, England) 55 (1): 20-31.
- ↑ Jason LA, Corradi K, Gress S, Williams S, Torres-Harding S (2006). Causes of death among patients with chronic fatigue syndrome. Health care for women international 27 (7): 615-26.
- ↑ Smith WR, Noonan C, Buchwald D (2006). Mortality in a cohort of chronically fatigued patients. Psychological medicine 36 (9): 1301-6.
- ↑ Sophia's story
- ↑ includeonly>"Fatigue syndrome ruling welcomed", 2006-06-23. Retrieved on 2007-09-03. (in English)
- ↑ Inquest Implications: Marshall E, Williams, M, June 2006
- ↑ Walsh CM, Zainal NZ, Middleton SJ, Paykel ES (2001). A family history study of chronic fatigue syndrome.. Psychiatr Genet 11 (3): 123-8. PMID 11702053.
- ↑ Chronic Fatigue Syndrome Demographics. (htm) Centers for Disease Control and Prevention. URL accessed on 2008-02-07.
- ↑ Craig, T and Kakumanu S (Mar 2002). Chronic fatigue syndrome: evaluation and treatment. Am Fam Physician. 65 (6): 1083-90. PMID 11925084.
- ↑ van de Glind G, de Vries M, Rodenburg R, Hol F, Smeitink J, Morava E (2007). Resting muscle pain as the first clinical symptom in children carrying the MTTK A8344G mutation.. Eur J Paediatr Neurol. PMID 17293137.
- ↑ Vojdani A, Thrasher J (2004). Cellular and humoral immune abnormalities in Gulf War veterans.. Environ Health Perspect 112 (8): 840-6. PMID 15175170.
- ↑ Bruno RL, Creange SJ, Frick NM (1998). Parallels between post-polio fatigue and chronic fatigue syndrome: a common pathophysiology?. Am J Med. 105 (3A): 66S-73S. PMID 9790485.
- ↑ Gaudino EA, Coyle PK, Krupp LB (1997). Post-Lyme syndrome and chronic fatigue syndrome. Neuropsychiatric similarities and differences.. Arch Neurol 54 (11): 1372-6. PMID 9362985.
- ↑ van Staden WC (2006). Conceptual issues in undifferentiated somatoform disorder and chronic fatigue syndrome.. Curr Opin Psychiatry 19 (6): 613-8. PMID 17012941.
- ↑ Jenkins R, Mowbray J, ed. Post-viral Fatigue Syndrome. 1991 John Wiley & Sons Ltd
- ↑ Bradley LA, McKendree-Smith NL, Alarcon GS (2000). Pain complaints in patients with fibromyalgia versus chronic fatigue syndrome.. Curr Rev Pain 4 (2): 148-57. PMID 10998728.
- ↑ Friedberg F, Jason LA (2001). Chronic fatigue syndrome and fibromyalgia: clinical assessment and treatment.. J Clin Psychol. 57 (4): 433-55. PMID 11255201.
- ↑ Pall ML, Satterlee JD (2001). Elevated nitric oxide/peroxynitrite mechanism for the common etiology of multiple chemical sensitivity, chronic fatigue syndrome, and posttraumatic stress disorder.. Ann N Y Acad Sci 933: 323-9. PMID 12000033.
- ↑ Aaron LA, Herrell R, Ashton S, Belcourt M, Schmaling K, Goldberg J, Buchwald D (2001). Comorbid clinical conditions in chronic fatigue: a co-twin control study.. J Gen Intern Med 16 (1): 24-31. PMID 11251747.
- ↑ Sinaii N, Cleary SD, Ballweg ML, Nieman LK, Stratton P (2002). High rates of autoimmune and endocrine disorders, fibromyalgia, chronic fatigue syndrome and atopic diseases among women with endometriosis: a survey analysis.. Hum Reprod 17 (10): 2715-24. PMID 12351553.
- ↑ Rogers, Richard (1997). Clinical Assessment of Malingering and Deception, Second Edition, pg 40 of 525, New York, London: Guilford Press.
- ↑ Malleson, Andrew (2005). Whiplash and Other Useful Illnesses, pg 59 of 544, Quebec: McGill-Queen's Press.
- ↑ Van Houdenhove B, Neerinckx E, Onghena P, Vingerhoets A, Lysens R, Vertommen H (2002). Daily hassles reported by chronic fatigue syndrome and fibromyalgia patients in tertiary care: a controlled quantitative and qualitative study.. Psychother Psychosom 71 (4): 207-13. PMID 12097786.
- ↑ Action for M.E. in the UK, Severely Neglected: Membership Survey London: Action for M.E.; 2001
- ↑ 286.0 286.1 286.2 Prins JB, Bos E, Huibers MJ, Servaes P, van der Werf SP, van der Meer JW, Bleijenberg G (2004). Social support and the persistence of complaints in chronic fatigue syndrome.. Psychother Psychosom 73 (3): 174-82. PMID 15031590.
- ↑ Colby J (2007). Special problems of children with myalgic encephalomyelitis/chronic fatigue syndrome and the enteroviral link.. J Clin Pathol 60 (2): 125-8. 16935964.
- ↑ Looper KJ, Kirmayer LJ (2004). Perceived stigma in functional somatic syndromes and comparable medical conditions.. J Psychosom Res 57 (4): 373-8. PMID 15518673.
- ↑ Clarke JN (1999). Chronic fatigue syndrome: gender differences in the search for legitimacy.. Aust N Z J Ment Health Nurs 8 (4): 123-33. PMID 10855087.
- ↑ Jason L, Corradi K, Gress S, Williams S, Torres-Harding S (2006). Causes of death among patients with chronic fatigue syndrome.. Health Care Women Int 27 (7): 615-26. PMID 16844674.
- ↑ Green J, Romei J, Natelson BH (1999) Stigma and Chronic Fatigue Syndrome Journal of Chronic Fatigue Syndrome, Vol. 5, No. 2, 1999
- ↑ Sydenham T, "The Works of Thomas Sydenham, M.D.", (translated from the Latin edition of Greenhill WA by Latham RG), Vol. 1, Londen, Sydenham Society, 1847
- ↑ Beard, G. (1869, Apr. 28). "Neurasthenia, or nervous exhaustion". The Boston Medical and Surgical Journal. (pp. 217-221)
- ↑ R.A.A. Pellew, J.A.R. Miles, "Further investigations on a disease resembling poliomyelitis seen in Adelaide," Medical Journal of Australia, 42. 480-482
- ↑ A.L. Wallis, "An investigation into an unusual illness seen in Epidemic and Sporadic Form in a General Practice in Cumberland in 1955 and subsequent years", M.D. Thesis, Edinburgh University, 1957
- ↑ Richardson J (2002) Myalgic Encephalomyelitis: Guidelines for Doctors. Journal: J of Chronic Fatigue Syndrome, Vol. 10(1)
- ↑ McEvedy CP, Beard AW (1970). Concept of benign myalgic encephalomyelitis. British medical journal 1 (5687): 11–5. Full text at PMC: 1700895
- ↑ Compston ND (1978). Epidemic myalgic encephalomyelitis. British medical journal 1 (6125): 1436–7.
- ↑ Johnson, Hilary (1996). Osler's Web: Inside the Labyrinth of the Chronic Fatigue Syndrome Epidemic, 24, New York: Penguin Books.
- ↑ Day W (1987), "Raggedy Ann Syndrome", Hippocrates: July/August, cover story
- ↑ Fukuda K, Straus S, Hickie I, Sharpe M, Dobbins J, Komaroff A (1994). The chronic fatigue syndrome: a comprehensive approach to its definition and study. International Chronic Fatigue Syndrome Study Group. Ann. Intern. Med. 121 (12): 953-9.
- ↑ Royal Colleges of Physicians, Psychiatrists and General Practitioners (1996). Chronic fatigue syndrome; Report of a joint working group of the Royal Colleges of Physicians, Psychiatrists and General Practitioners, London, UK: Royal College of Physicians of London.
- ↑ David A, Wessely S (1993). Chronic fatigue, ME, and ICD-10. Lancet 342 (8881): 1247–8.
- ↑ Vercoulen JHMM, Swanink CMA, Galama JMD, Fennis JFM, Jongen PHJ, Hommes OR, Van der Meer JWM, Bleijenberg G. (1998), "The persistence of fatigue in chronic fatigue syndrome and multiple sclerosis: Development of a model. Journal of Psychosomatic Research", 45, 507 – 517
- ↑ Song, S, Jason, LA (2005), "A population based study of CFS experienced in differing patient groups. An effort to replicate Vercoulen et al.'s model of CFS", Journal of Mental Health, 14, 3, 277-289
Articles about ME/CFS
| Proposed Causes|
|This page uses Creative Commons Licensed content from Wikipedia (view authors).|